JPS60126271A - Quinolonecarboxylic acid derivative - Google Patents

Quinolonecarboxylic acid derivative

Info

Publication number
JPS60126271A
JPS60126271A JP23256083A JP23256083A JPS60126271A JP S60126271 A JPS60126271 A JP S60126271A JP 23256083 A JP23256083 A JP 23256083A JP 23256083 A JP23256083 A JP 23256083A JP S60126271 A JPS60126271 A JP S60126271A
Authority
JP
Japan
Prior art keywords
formula
compound
water
added
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP23256083A
Other languages
Japanese (ja)
Inventor
Tsutomu Irikura
勉 入倉
Seigo Suzue
清吾 鈴江
Satoru Murayama
哲 村山
Keiji Hirai
敬二 平井
Takayoshi Ishizaki
孝義 石崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to JP23256083A priority Critical patent/JPS60126271A/en
Priority to IN353/MAS/84A priority patent/IN159604B/en
Priority to PT7961684A priority patent/PT79616A/en
Priority to DK586284A priority patent/DK586284D0/en
Priority to FI844839A priority patent/FI844839L/en
Publication of JPS60126271A publication Critical patent/JPS60126271A/en
Pending legal-status Critical Current

Links

Landscapes

  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NEW MATERIAL:A compound expressed by formula I (R is H, methyl or p-aminobenzyl; Y is Cl, F or methyl) and a hydrate and salt thereof. EXAMPLE:1-Cyclopropyl-6, 8-difluoro-7-( 1-piperazinyl )-4-oxoquinoline-3-carboxylic acid. USE:An antimicrobial agent, effective against Gram-negative and Gram-positive bacteria, and having characteristics of easy absorption and a lower alkyl group or p-aminobenzyl group bonded to the piperazine or a halogen group introduced into the 8-position. PREPARATION:A novel compound expressed by formula II (R<1> is H or alkyl; X is halogen) is condensed with a compound expressed by formula III (R<2> is H, p-nitrobenzyl or p-aminobenzyl), and the resultant condensate is hydrolyzed when R<1> is an alkyl group or further reduced when R<2> is p-nitrobenzyl to afford the aimed compound expressed by formula I .

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は一般式 (式中、)たは水素、メチルまたは1〕−アミノペンデ
ルを、Yは塩素、弗素またはメチルを示す)で表わされ
る新規なキノロンカルボン酸誘導体、その塩、その製造
方法、およびその抗菌剤としての用途に関Jる。 本発明の化合物は、本発明者らにより新規に合成され、
先行技術によるキノロンカルボン酸よりも試験管内の抗
菌活性がダラム陽性並びに陰性菌と広範囲に及び且つ低
用最で効果を5R,1irfするばかりでなく、動物に
於て吸収が良好な特性を有づる事が発見され、本発明に
至ったのである。 次に本発明化合物の製造り法について説明ける。 (u) 〔x〕 (式中、Xはハロゲンを、R′は水素または低級アルキ
ル、]<″は水素、メチル、p−二1− uペンデル、
またはp−アミノペンデルを示し、YおよびRは前記に
同じ) すなわち、式[II]で表わされる化合物を式[I[[
J ?l−表わされる化合物と反応させることにより弐
「1]で表わされる本発明化合物が合成される。ただし
式[II[]でRnがp−ニトロペンデルの化合物の場
合は式[II]で表わされる化合物との反応成績体を常
法に従って還元し、ニトロ基をアミノ基に変換して本発
明化合物にする事が出来る。 また式[nlでR′が低級アルキルの化合物の場合は式
II]で表わされる化合物との反応成績体を常法に従っ
て加水分解してエステルをカルボン酸に変換して本発明
化合物にづる事が出来る。 式[I[]で表わされる化合物と式[I[1]で表わさ
れる化合物の反応は無溶媒下あるいは水、アルコール類
、ジメチルホルムアミド(DMF>、ジメチルスルホキ
シド(DMSO) 、ヘキサメチルボスポリツクアミド
、ピリジン、ピコリンのような極性溶媒の存在下で行な
う。反応温度は室温〜200℃、好ましくは60〜16
0℃の範囲で適当に選択される。更に詳しくは式[II
]で表わされる化合物と2〜5倍モルの式[I[1]で
表わされる化合物を2〜10倍容の前記溶媒中で、80
〜120°Cに1〜数時間加熱するのが好適である。ま
た式[1]で表わされる化合物は所望ならば、その塩に
常法に従って変換づる事が出来る。塩としては例えば組
り硫酸、燐酸等の無機酸との塩、メタンスルホン酸、乳
酸、酢酸等の有機酸との塩、あるいはカルボン酸のナト
リウム塩、カリウム塩、マグネシウム塩、カルシウム塩
、アルミニウム塩、セリウム塩、りUム塩、コバルト塩
、銅塩、鉄塩、亜鉛塩、銀塩等が挙げられる。 本発明の出発物質である一般式LI[]で表わされる化
合物もまた、新規化合物であり、例えば次に示されるよ
うなルートで合成する事が出来る。 出発化合物となる2、3.4.5−テトラフルオロ二1
−〇ベンゼンは公知であり、例えば1,2゜3.4−テ
トラフルオロベンゼンを二1−口化し゛C製’lli 
t ルコJニーができル((Tetrahedron、
 23.4719、 1967年)。 −〉 し\ 本発明の一般式[IIで表わされる化合物およびその水
和物並びにその塩はグラム陰性菌およびダラム陽性菌に
対して優れた抗菌特性を示す。医薬品として使用される
場合吸収が良好なことが望まれる。その為にピペラジン
に低級アルキル基又はp−アミノペンデル基をつけたり
、8位にハロゲン基を尋人することにより吸収性を高め
たものである。本発明にか)る薬物は通常の医薬品とし
ての大または動植物への投与形態および経路によるが、
従来薬学的に良く知られた形態および経路即ち、錠剤、
カプレル、散剤、軟壽、注rfJ液、点眼剤、生薬等に
適用される。 次に本発明の化合物の製造方法およびその抗菌特性を実
施例をもって詳細に説明する。 実施例1 2−シクロプロピルアミノ−3,4゜5−ト
リフルオロニトロベンゼン 2、3.4.5−テトラフルオロニ1〜ロベンピン3.
1gのトルエン20d溶液にシクロプロピルアミン2d
の1−ルエン5#li!溶液を10℃以下で加え、室温
1時間攪拌した。反応溶液にベンゼン50mおよび氷水
20@ijを加え有m層を分取し、水洗、無水芒硝乾燥
、減圧濃縮後、残漬をフラッシュカラムにより精製し、
目的物2.55Kgおよび4−シクロプロピルアミノ−
2.3.5−1−リフルオロニトロベンゼンを単離した
。 実施例2 2−(N−シクロプロピル)アセ1〜アミド
−3.4.5−I−リフルオロニトロベンゼンの合成 シクロプロピルアミノ体(実施例2 ) 0.9 gの
無水酢酸10d溶液にIIl硫酸を2滴加えると光熱し
、溶液のオレンジ色が瞬時に消失する。5分後、反応溶
液を氷−炭酸カリ水溶液に注ぎ、エーテルで抽出する。 水、エーテル層を希塩酸、水で洗い、無水芒硝乾燥後溶
媒を留去し、残渣をヘキサンから再結晶して目的物0.
868 gを得る。淡黄緑色プリズム品、融点91−9
2℃。 元素分析:計紳値(C+ + Hc4F3 Nz 03
 )、C: 48.19. H: 3.31. N :
 10,21実測値 C: 48.53. H: 3.30. N : 10
,31゜実施例3 2−(N−シクロプロピル)アセト
アミド−3,4,5−1−リフルオロアニリンの合成 7 tチル体(実施例2 ) 0.8 gをエタノール
40mftおよび酢酸207の混合溶液に溶解し、10
%Pd/ C200m!Iを加え50分間冨圧で水素添
加を行なう。 反応液を濾過後、減圧濃縮し残渣をクロロボルム100
#li!に溶解しΦ炭酸ソーダ水溶液、水で順次洗い、
無水芒硝で乾燥し溶媒留去して冑られる残渣をエタノー
ルから再結晶して目的物0.534 ”jを得る。淡褐
色プリズム晶、融点171〜173℃。 元素分析二61算値(C+ + l−1+ IFa N
Z 0B )、C: 54,10. I−1: 4,5
4. N : 11.47 。 実測値 C: 54.26 1」: 4.57. N : 11
.50゜実施例4 N−(2,3,4,−t〜リフルオ
ロフェニル)−N−シクロプロピルアセトアミドの合成 アニリン体(実施例3 ) 1.26gを無水ジメチル
ホルムアミド(DMF)10dに加え、新たに蒸留した
亜硝酸アミル0,92j7の無水D M F 5 ml
溶液を60〜65℃で20分間で滴下した。冷接、エー
テル150mQを加え、41133層を水、希塩酸およ
び水で順次洗浄し、無水芒硝乾燥しで濃縮し、残渣をフ
ラッシュカラム<2:3.n−ベキ4ナン:酢酸エチル
)ににり精製して目的物0.95gを得た。0−ヘキサ
ンから再結晶すると、無色帽状結晶、融点99〜100
℃となる。 元素分析:計紳値(C+ lH+□ F3 NzO>、
C: 57.64. H: 4,40. N : 6.
it。 実測値 C: 57.85. H: 4,32. N : t3
.11゜実施例5 N−シクロプロピル−2,3,4゜
−トリフルオロアニリンの合成 アセトアミド体〈実施例4)950#1gを10%苛性
ソーダ液30rdおよびエタノール10IIdlの混合
液にIノロえ80〜b し水洗、無水芒硝乾燥して濃縮し、淡褐色油状の目的物
0.63gを得た。 実施例6 ジエチル N−シクロプロピル−N−(2,
3,4,−トリフルオロフェニル)アミノメチレンマロ
ネートの合成 アニリン体(実施例5)0.6SFおよびエトキシメチ
レンマロン酸ジエチル1.Onを混合し150〜190
℃で1.5時間攪拌した。冷却後、フラッシュカラムく
 0−ベキ4ナンー酢酸エチル)により精製して無色油
状の目的物0.66SFを得た。 実施例7 1チル 1−シクロプロピル−6゜7.8−
トリフルオロ−1,4−ジヒドロ−4−4キ−j士71
Iゝ/ −Q −1+ルポ本シレートの合成マロネー(
一体〈実施例5) 5541ngをポリリン酸4gに加
え、120〜130℃で1時間攪J$ L/ 1こ。冷
接、氷水を加えクロロホルム抽出し無水芒硝乾燥後濃縮
し、残渣をフラッシュカラム(1:3.酢酸エチル:塩
化メチレン)により精製しアセトニトリルから再結晶し
て無色針状晶の目的物230m1を得/j。 元素分析:計算値(C+ s l−1t z F3NO
3)、C: 57.88. l−1: 3.’89. 
N : 4,50゜実測値 C: 57.68. H: 3.74. N : 4.
50゜実施例8 1−シクロプロピル−6,8−ジフル
オロ−1,4ジヒドロ−7−(4−メチル−1−ピペラ
ジニル)−4−オキソキノリン−3−力ルボン酸の合成 カルボキシレート体(実施例7 ) 206Il+yお
よびN−メチルピペラジン200 m9 ジメチルスル
小キシド(DMSO)5−に加え90〜100℃で2時
間攪拌した。濃縮後、残渣をクロロホルム60tdに溶
解し、クロロホルム層を炭酸カリ水溶液a3よび水で洗
い、無水芒硝乾燥後、濃縮して得られる残漬に1N苛性
ソーダ101dlを加え沸騰水浴上で1時間攪拌した。 不溶物を濾去し、濾液を酢酸でI)H7に調整して濃縮
した。 残漬を高速液体クロマトグラフィー(Ol)S−C’+
 a 、 5.4%アンモニア水:メタノール−5=9
5〜30ニア0)により分取し、さらにシリカゲルカラ
ム(クロロホルムからクロロホルム:メタノール:濶ア
ンモニア水=10: 10.: 3 )により精製し、
メタノールから再結晶して無色針状晶の目的物63mg
を得1c0融点220〜221℃。 元素分析:計算値(C+ s H+ sF2 N303
 )、C: 59.50. H: 5.27. N :
 11,56゜実測値 C: 59.24. ト1 : 5.21. N : 
11,47実施例9 1−シクロプロピル−6,8−ジ
フルオロ−7ビペラジニルー4−オキソキノリン−3−
カルボン酸の合成 カルボキシレート体〈実施例7)30■およびピペラジ
ン40tngをDMSoldに加え90〜100℃で1
時間攪拌した。以後、実施例8と同様に処理し、メタノ
ールから再結晶してクリーム色の針状品の目的物8’m
l’Fr得た。融点270℃〜(分解)。 元素分析:計算値(C+ 78+ 7 F’2 Nz 
03 >、C: 58.45. H: 4.91. N
 : 12.03゜実測値 C: 58.37. H: 4.89. N : 12
,20゜試験例1 抗菌スペクトル 抗菌試験は日本化学療法学会指定の方法に準じて実施さ
れた。その結果を次表に示す。  − L \ 古づ 七 ^ 試験例2 マウス全身感染症に対する効果1群5匹のI
CRマウスを用い、腹腔内に大腸菌(E、 coli 
ML 4707)を4.9 xioa菌数/マウス注入
し、その1時間後に薬物を7用量夫々−回径口投与し、
薬物用量と生存率のカーブから50%の動物が死を免れ
治癒する用fit(E[)50)をめた。表2にその結
果を示す。 本発明の実施例8化合物はオフロキサチンの約6倍、ノ
ルフロキサチンの約33倍活性が高かった。 表 2 (llly/d) ED50(ll+9/Kg)実施例
8 化合物 0.025 0.15 オフロキサチン 0.05 0,90 ノルクロキサチン 0.05 5.0 手続′:4市正書(自発) 昭和59年7月30しl 特許庁長官 志 賀 学 殿 1、事件の表示 昭和58年 特清願 第232560号2、発明の名称 キノロンカルボン酸誘導体 3、補正をする者 事件との関係 特許出願人 住 所 東京都千代田区神田駿河台2丁目5番地名 称
 (139)杏林製桑株式会礼 4、代理人 住 所 東京都千代田区神田北乗物町16番地〒101
 英 ビル3階 6、補正の対象 明 細 書 1、発明の名称 キノロンカルボン酸誘導体 2、特許請求の範囲 (1)一般式 (式中、Rは水素、メチルまたはp−アミノペンデルを
、Yは塩素、弗素またはメチルを示す)で表わされる化
合物およびその水和物並びにその塩。 (式中、RIは水素または低級アルキル、Xはハロゲン
、Yは塩素、弗素またはメチルを示す) で表わされる化合物と 一般式 (式中、R2は水素、メチル、p−ニトロペンデルまた
はp−アミノペンデルを示′!l)で表わされる化合物
を縮合させ、R1が低級アルキルの場合は更に加水分解
づるが、あるいはR2がp−ニトロペンデルの場合は更
に還元することを特徴とする特許請求の範囲第1項記載
の一般式(I)であられされる化合物およびその水和物
並びにその塩の製造方法。 3、発明の詳細な説明 本発明は一般式 (式中、Rは水素、メチルまたはp−アミノペンデルを
、Yは塩素、弗素またはメチルを示す)で表わされる新
規なキノロンカルボン酸誘導体、その塩、その製造方法
、およびその抗菌剤としての用途に関する。 本発明の化合物は、本発明者らにより新規に合成され、
先行技術によるキノロンカルボン酸よりも試験管内の抗
菌活性がダラム陽性並びに陰性菌と広範囲に及び且つ低
用量で効果を発揮するばかりでなく、動物に於て吸収が
良好な特性を有する事が発見され、本発明に至ったので
ある。 次に本発明化合物の製造方法について説明する。 (式中、Xはハロゲンを、R1は水素または低級アルキ
ル、R2は水素、メチル、p−二1〜口ベンヂル、また
はp−アミノペンデルを示し、YおよびRは前記に同じ
) すなわち、式CII]で表わされる化合物を式[II[
]で表わされる化合物と反応させることにより式[1]
で表わされる本発明化合物が合成される。ただし式[1
[1]でR2がp−ニトロペンデルの化合物の場合は式
[1]で表わされる化合物との反応成績体を常法に従っ
て還元し、ニトロ基をアミノ基に変換して本発明化合物
にする事が出来る。また式[、I[]でR1が低級アル
キルの化合物の場合は式[I[[]で表わされる化合物
との反応成績体を常法に従って加水分解して」ニスチル
をカルボン酸に変換して本発明化合物にする事が出来る
。 式[II]で表わされる化合物と式[111]で表わさ
れる化合物の反応は無溶媒下あるいは水、アルコール類
、ジメチルボルムアミド(DMF)、ジメチルスルホキ
シド(DIv’l5O)、ヘキザメチルホス小リックア
ミド、ピリジン、ピコリンのような極性溶媒の存在下0
行なう。反応温度は室温〜200℃、好ましくは60〜
160℃の範囲で適当に選択される。更に詳しくは式[
1[]で表わされる化合物と2〜5倍モルの式[111
]で表わされる化合物を2〜10倍容の前記溶媒中で、
60〜120℃に1〜数時間加熱するのが好適である。 また式[IIで表わされる化合物は所望ならば、その塩
に常法に従って変換する事が出来る。塩としては例えば
塩酸、硫酸、燐酸等の無機酸との塩、メタンスルホン酸
、乳酸、酢酸等の有機酸との塩、あるいはカルボン酸の
すトリウムW、カリウム塩、マグネシウム塩、ノコルシ
ウム塩、アルミニウム塩、セリウム塩、りL1ム塩、コ
バル]〜塩−1鯛塩、鉄塩、亜鉛塩、銀塩等が挙げられ
る。 本発明の出発物質である一般式[11で表わされる化合
物もまた、新規化合物であり、例えば次に示されるよう
なルートで合成する事が出来る。出発化合物となる2、
3,4.5−テトラフルオロニトロベンゼンは公知であ
り、例えば1,2,3゜4−デトラフルオロベンゼンを
ニトロ化して製造することができる(Tetrabed
ron、 23.4719゜1967年)。 Lム 本発明の一般式[I]で表わされる化合物およびその水
和物並びにその塩はグラム陰性菌およびダラム陽性菌に
対して優れた抗菌特性を示づ一0医薬品として使用され
る場合吸収が良好なことが望まれる。その為にピペラジ
ンに低級アルキル基又はp−アミノペンデル基をつけた
り、8位にハロゲン基を導入することにより吸収性を高
めたものである。本発明にか)る薬物は通常の医薬品と
しての大または動植物への投与形態および経路によるが
、従来薬学的に良く知られた形態および経路即ち、錠剤
、カプセル、散剤、軟膏、注射液、点眼剤、生薬等に適
用される。 次に本発明の化合物の製造方法およびその抗菌特性を実
施例をもって詳細に説明づる。 実施例1 2−シクロプロピルアミノ−3,4,5−トリフルオー
口二トロベンゼンの合成 2.3,4.5−テトラフルオロニトロベンゼン3.1
9のトルエン20a!!溶液にシクロプロピルアミン2
−のトルエン5−溶液を10℃以下で加え、室温1時間
攪拌した。反応溶液にベンゼン50iIIi!および氷
水20mを加え有機層を分取し、水洗、無水芒硝乾燥、
減圧濃縮後、残漬をフラッシュカラムにより精製し、目
的物2,559および4−シクロプロピルアミノ−2,
3,51−リフルオロニトロベンゼンを単離した。 実施例2 2−(N−シクロプロピル)アセトアミド−3゜4.5
−1−リフルオロ二1−ロベンゼンの合成シクロプロピ
ルアミノ体(実施例1”) 0.9 gの無水酢酸10
#Ii!溶液に濃硫酸を2滴加えると発熱し、溶液のオ
レンジ色が瞬時に消失する。5分後、反応溶液を氷−炭
酸カリ水溶液に注ぎ、エーテルで抽出する。エーテル層
を赤組り水で洗い、無水芒硝乾燥後溶媒を留去し、残渣
をヘキサノから再結晶して目的物0.868 gを得る
。 淡黄緑色プリズム晶、融点91〜92℃。 元素分析: C1189F3 N203g1算1a C
: 48,19 、 H: 3,31. N : 10
.21実測値 C: 48,53 、ト1 : 3,3
0. N : 10.31実施例3 2−(N−シクロプロピル)アセトアミド−3゜4.5
−トリフルメロアニリンの合成 アセチル体(実施例2 ) 0.8 gをエタノール4
0Idおよび酢酸20−の混合溶液に溶解し、10%P
d /C20(lI#を加え50分間常圧で水素添加を
行なう。反応液を濾過後、減圧濃縮し残漬をクロロホル
ム100Idに溶解し重炭酸ソーダ水溶液、水で順次洗
い、無水芒硝で乾燥し溶媒留去しτ1qられる残渣々エ
タノールから再結晶して目的物0.534 gを得る。 淡褐色プリズム晶、融点171〜173℃。 元素分析: C11f」u Fs NZ 03計算値 
C: 54.10 、 H: 4.54. N : 1
1.47実測値 C: 54.26 、 H: 4,5
7. N : 11.50実施例4 N −(2,3,4−トリフルオロフェニル)−N−シ
クロプロピルアセ1−アミドの合成 アニリン体(実施例3 ) 1.26gを無水ジメチル
ホルムアミド(DMF)10tdに加え、新たに蒸留し
た亜硝酸アミル0.92yの無水DMF5IrR溶液中
に60〜65℃で20分間で滴下した。冷接、エーテル
150Idを加え、有機層を水、希塩酸および水で順次
洗浄し、無水芒硝乾燥して濃縮し、残渣をフラッシュカ
ラム(2:3.n−へキサン:酢酸エチル〉により精製
して目的物0.95gを得た。n−ヘキサンから再結晶
すると、無色剣状結晶、融点99〜100℃となる。 元素分析: Cu HIOF3 N20計算値 C: 
57.64 、 )(: 4.40. N : 6.1
1実測1aC: 57.85 、1−(: 4.32.
 N : 6.11実施例5 N−シクロプロピル−2,3,4−トリフルオロアニリ
ンの合成 アセトアミド体(実施例4)950mgを10%苛性ソ
ーダ液30mおよびエタノール1(ldの混合液に加え
80〜90℃で4時間攪拌した。6後ニーデル抽出し水
洗、無水芒硝乾燥して濃縮し、淡褐色油状の目的物0.
63SFを得た。 実施例6 ジエチル N−シクロプロピル−N−(2,3゜4−ト
リフルAO〕1ニル)アミノメチレンマロネートの合成 アニリン休(実施例5 ) 0.6 gおJ、びエトキ
シメチレンマロン酸ジエチル1.04gを混合し150
〜160℃で1.5時間攪拌した。冷却後、フラッシュ
カラム(n−ヘキサンー酢酸エチル)により精製して、
無色油状の目的物0.665Fを得た。 実施例7 エチル 1−シクロプロピル−6,7,8−トリフルオ
ロ−1,4−ジヒドロ−4−オキソキノリン−3−カル
ボキシレートの合成 マロネート体(実施例6) 554mgをポリリン酸4
gに加え、120〜130℃で1時間攪拌した。 冷接、氷水を加えクロロホルム抽出し無水芒硝乾燥後濃
縮し、残漬をフラッジ1カラム(1:3、酢酸エチル:
塩化メチレン)により精製しアセトニトリルから再結晶
して無色針状晶の目的物23GIAIを得た。 融点1
75〜176℃元素分析: C+s H+2Fa NO
3劇算値 C: 57.88. ト1 : 3,89.
 N : 4.50実測値 C: 57,68. l−
1: 3.74. N : 4.50実施例8 1−シクロプロピル−6,8−ジフルオロ−1,4−ジ
ヒドロ−7−(4−メチル−1−ごペラジニル)−4−
オキソキノリン−3−カルボン酸の合成カルボキシレー
]一体(実施例7 ) 206iyおよびN−メチルピ
ペラジン20(mをジメチルスル小キシド(DMS’0
)5dに加え90〜100℃で2時間攪拌した。濃縮後
、残渣をクロロホルム60mに溶解し、クロロホルム層
を炭酸カリ水溶液および水で洗い、無水芒硝乾燥後、濃
縮して得られる残渣に1N苛性ソーダ10dを加え沸騰
水浴上で1時間攪拌した。不溶物を濾去し、濾液を酢酸
でPH7に調整して濃縮した。 残漬を高速液体りOマドグラフィー(ODS−CI+、
5.4%アンモニア水:メタノール−5=95〜30:
間)により分取し、さらにシリカゲルカラム(クロロホ
ルムからクロロホルム:メタノール:濃アンモニア水−
10: 10: 3 )により精製し、メタノールから
再結晶して無色釧状晶の目的物G3tasを得た。融点
220〜221℃。 元素分析: Cva l−ll9FZ N303計算値
 C: 59.50. ト1 : 5.27. N :
 11,56実測111i C: 59,24. )−
に5.21. N : 11,47実施例9 1−シクロプロピル−6,8〜ジフルAO−7−(1−
ピペラジニル)−4−71キソキノリン−3−カルボン
酸の合成 カルボキシレート体(実施例7 ) 30mgおよびピ
ペラジン40IRgをDMSOI蛇に加え90・〜10
0℃で1時間攪拌した。以後、実施例8と同様に処理し
、メタノールから再結晶してクリーム色の針状晶の目的
物8111gを得た。 融点270℃〜(分解)。 元素分析: C+r I」+r Fz Nz Os計算
値 C: 58.45. l−1: 4.91. N 
: 12.03実測値 C: 58,37. ト1 :
 4,89. N : 12.20実施例10 1−シクロプロピル−6,8−ジフルオロ−1,4−ジ
ヒドロ−7−(1〜ピペラジニル)−4−Aキソキノリ
ン−3−カルボン酸エチルの合成 ごペラジン1.13 gのジメチルスルホキシド15d
溶液にカルボキシレート体(実施例7)0.82 gを
加え、60℃で2時間撹拌した。冷接、反応液にクロロ
ホルム200mを加え、炭酸カリウム水溶液で洗浄後1
%塩酸で抽出し、抽出液を水酸化ナトリウム水溶液でP
I−110〜11として素早くクロロボルムで抽出した
。クロロホルム層を水洗、無水芒硝で乾燥後、結晶が析
出しはじめるまで濃縮しI熱ア廿トンを加え、冷接、析
出晶を濾取し無色11状品の目的物(1,87gを得た
。 融点211〜212℃ 元素分析:C四H21F2 N30s 計算値 C: 13(1,47、H: 5.61 、 
N : 11,13実測値 G : 60.50 、ト
1 : 5.50 、 N : 11,14実施例11 1−シクロプロピル−6,8−ジフルオロ−1,4−ジ
ヒドロ−1−(1−ピペラジニル)−4−Aキソキノリ
ン−3−カルボン酸の合成 カルボン酸エチル体(実施例10)0.879を1N水
酸化ナトリウム水溶液20dに加え、100℃で1時間
撹拌した。冷接、反応液を酢酸で中和して析出物を濾取
し、メタノールから再結晶して無色プリズム晶の目的物
o、eo gを得た。 融点270〜270.5℃(分
解)元素分析: Car H+r F2 N303 ・
M)−1z O計算値 C: 57.71 、 )−1
: 4.99 、 N : 11.88実測値 G :
 57.85 、 It : 11.92 、 N 7
11.&8試験例1 抗菌スペクトル 抗菌試験は口重化学療法学会指定の方法に準じて実施さ
れた。その結果を次表に示す。 試験例2 マウス全身感染症に対する効果 1群5匹のIORマウスを用い、腹腔内に大腸菌(E、
 coli ML 4707)を4.9x106個/マ
ウスまたは緑膿菌(P、aeruoinosa I I
[)1210)を3,5X 105個/マウスを注入し
、その1時間後に薬物を7用量夫々−回径口投与し、薬
物用量と生存率のカーブから50%の動物が死を免れ治
癒する用ff1(ED50)をめた。表2にその結果を
示づ。 本発明の実施例8化合物、実施例9化合物は、対照とし
て用いたシプロフロキサシンに比し、非常に優れた感染
防禦効果を示した。 −J〜げ5ネ山正毬; (白 光) 昭和59iT:11月29[1 特If庁長官 志 rq 学 殿 III和58年 特ffi’FIlfi ff+232
560Q2、発明の名称 キノロンカルボン酸誘導イ木 3、補正をする者 事件との関係 特許出願人 住 所 東京都千代田区神田駿河台2丁目5番地名 称
 (139)杏林賢鵬・2、J(会社4、代理人 住 所 東京都千代[i1区神Ll]北乗物町16番地
〒101 英 ヒル3階 5、補正により増加覆る発明の数 2 6、補正の対象 IV床117B全文 明 9■ 出 1、発明の名称 キノl」ンカル小ン酸誘導体 2、!l寺晶′1i青j乏の範囲 (式中、R(よ水素、メチル、1)−二l−D /\ン
シルまたは11−アミツノベンシルを、Y LL li
 i、弗畠またはメチルを示り゛)で表わされる化合物
およびその水和物並ひにての塩。 (式中、R’は水素また(よ低嶽アルーAル、×けハロ
ゲン、Yは塩素、弗f、z4ま/jはメチルを承り)で
表わされる化合物と 一般式 〈式中、Rは水素、メチル、p−l−Dノ\ンジルまだ
(よい−アミノベンジルを示J) で表わされる化合物4縮含さU、1〈1か低〒1をアル
ギルの場合GJ更に加水分解Jるか、あるいは1でが1
〉−二1・・ロベンジルの揚台(ま更に還元づることを
特徴どする待豹品求の範囲第′11r!記載の一般式C
I)であられされる化合物おJ、びての水和物並びにそ
の塩の製造方法。 (3)一般式 n (式中、R1は水素または低級アルキル、Yは塙バ;、
弗素またはメf−ルを示す) で表わさ机る化合物に1)−二トロペンジルハライドを
縮〜合さけ、更にjU元し、要すればエステルを加水分
F17−!Jることを特徴とり−る。 一般式(■) 、−。 (式中、Rは1)−アミノベンジルを、Yは塩素、弗素
またはメチルを示す)で表わされる化合物およびその水
和物−1ρσにその塩のI!iU 3+17ノノ法。 /l )一般式 (式中、R1は水素または低級フルキル、Y
The present invention provides novel quinolone carboxylic acid derivatives represented by the general formula (in the formula: ) or hydrogen, methyl or 1]-aminopendel, Y represents chlorine, fluorine or methyl, salts thereof, and methods for producing the same; and its use as an antibacterial agent. The compound of the present invention was newly synthesized by the present inventors,
Compared to quinolone carboxylic acids according to the prior art, it has a wider range of in vitro antibacterial activity, including Durham-positive and -negative bacteria, and is not only effective at 5R and 1IRF with a low dosage, but also has the property of being better absorbed in animals. This discovery led to the present invention. Next, the method for producing the compound of the present invention will be explained. (u) [x] (wherein, X is halogen, R' is hydrogen or lower alkyl, ]<'' is hydrogen, methyl, p-21-u pendel,
or p-aminopendel, and Y and R are the same as above) That is, a compound represented by formula [II] is converted into a compound represented by formula [I[[
J? The compound of the present invention represented by 2 "1" is synthesized by reacting with the compound represented by l-.However, in the case of a compound of formula [II[] where Rn is p-nitropendel, the compound represented by formula [II] The compound of the present invention can be obtained by reducing the reaction product with a compound according to a conventional method and converting the nitro group to an amino group.Also, the compound of the present invention can be obtained by formula [formula II in the case of a compound where R' is lower alkyl in nl]. The compound of the present invention can be obtained by hydrolyzing the reaction product with the compound represented by the formula [I[1] and converting the ester into a carboxylic acid according to a conventional method. The reaction of the represented compounds is carried out in the absence of a solvent or in the presence of a polar solvent such as water, alcohols, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexamethylbospolitucamide, pyridine, or picoline.Reaction temperature is room temperature to 200°C, preferably 60 to 16
It is appropriately selected within the range of 0°C. More specifically, the formula [II
] and 2 to 5 times the mole of the compound represented by the formula [I[1] in 2 to 10 times the volume of the above solvent, and 80
Heating to ~120°C for 1 to several hours is preferred. Further, the compound represented by formula [1] can be converted into a salt thereof according to a conventional method, if desired. Examples of salts include salts with inorganic acids such as sulfuric acid and phosphoric acid, salts with organic acids such as methanesulfonic acid, lactic acid, and acetic acid, and sodium salts, potassium salts, magnesium salts, calcium salts, and aluminum salts of carboxylic acids. , cerium salt, rim salt, cobalt salt, copper salt, iron salt, zinc salt, silver salt and the like. The compound represented by the general formula LI[], which is the starting material of the present invention, is also a new compound, and can be synthesized, for example, by the route shown below. 2,3.4.5-tetrafluoro21 as the starting compound
-〇Benzene is well known, for example, 1,2゜3,4-tetrafluorobenzene is converted into 21-benzene and manufactured by C.
t Ruco J knee is possible ((Tetrahedron,
23.4719, 1967). ->shi\ The compound represented by the general formula [II of the present invention, its hydrates, and its salts exhibit excellent antibacterial properties against Gram-negative bacteria and Durham-positive bacteria. When used as a medicine, good absorption is desired. For this purpose, absorption is enhanced by attaching a lower alkyl group or p-aminopendel group to piperazine, or by adding a halogen group to the 8-position. The drug according to the present invention may be administered to animals or plants as a conventional pharmaceutical, depending on its administration form and route.
Traditionally pharmaceutically well-known forms and routes, i.e. tablets,
Applicable to caprels, powders, softgels, RFJ injections, eye drops, herbal medicines, etc. Next, the method for producing the compound of the present invention and its antibacterial properties will be explained in detail with examples. Example 1 2-cyclopropylamino-3,4°5-trifluoronitrobenzene 2,3.4.5-tetrafluoronitrobenzene 1-lobempine 3.
2 d of cyclopropylamine in 1 g of 20 d of toluene solution
1-Luene 5#li! The solution was added at below 10°C and stirred at room temperature for 1 hour. 50 m of benzene and 20 m of ice water were added to the reaction solution, the m-layer was separated, washed with water, dried with anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified using a flash column.
Target product 2.55Kg and 4-cyclopropylamino-
2.3.5-1-Lifluoronitrobenzene was isolated. Example 2 Synthesis of 2-(N-cyclopropyl)ace1-amido-3.4.5-I-lifluoronitrobenzene Cyclopropylamino compound (Example 2) Add IIl sulfuric acid to 0.9 g of acetic anhydride 10d solution When two drops of are added, the solution becomes heated and the orange color of the solution disappears instantly. After 5 minutes, the reaction solution is poured into ice-potassium carbonate aqueous solution and extracted with ether. The water and ether layers were washed with dilute hydrochloric acid and water, and after drying with anhydrous sodium sulfate, the solvent was distilled off, and the residue was recrystallized from hexane to yield the desired product.
Obtain 868 g. Pale yellow-green prism product, melting point 91-9
2℃. Elemental analysis: Total value (C+ + Hc4F3 Nz 03
), C: 48.19. H: 3.31. N:
10,21 Actual value C: 48.53. H: 3.30. N: 10
, 31゜Example 3 Synthesis of 2-(N-cyclopropyl)acetamide-3,4,5-1-lifluoroaniline 7 T-chill form (Example 2) 0.8 g was mixed with 40 mft of ethanol and 207 mft of acetic acid. Dissolved in solution, 10
%Pd/C200m! Add I and hydrogenate at full pressure for 50 minutes. After filtering the reaction solution, it was concentrated under reduced pressure and the residue was dissolved in chloroborm 100.
#li! Dissolve in Φ sodium carbonate aqueous solution, wash sequentially with water,
Dry with anhydrous sodium sulfate, evaporate the solvent, and recrystallize the residue from ethanol to obtain the desired product, 0.534"j. Pale brown prismatic crystals, melting point 171-173°C. Elemental analysis 261 calculation value (C + + l-1+ IFa N
Z 0B ), C: 54,10. I-1: 4,5
4. N: 11.47. Actual measurement value C: 54.26 1'': 4.57. N: 11
.. 50° Example 4 Synthesis of N-(2,3,4,-t~lifluorophenyl)-N-cyclopropylacetamide 1.26 g of aniline compound (Example 3) was added to 10 d of anhydrous dimethylformamide (DMF), 5 ml of freshly distilled amyl nitrite 0.92j7 anhydrous DMF
The solution was added dropwise over 20 minutes at 60-65°C. After cold addition, 150 mQ of ether was added, and the 41133 layer was washed successively with water, dilute hydrochloric acid, and water, dried with anhydrous sodium sulfate, concentrated, and the residue was passed through a flash column <2:3. The product was purified using ethyl acetate (n-benzene: ethyl acetate) to obtain 0.95 g of the desired product. Recrystallization from 0-hexane gives colorless cap-shaped crystals, melting point 99-100.
℃. Elemental analysis: Total value (C+ lH+□ F3 NzO>,
C: 57.64. H: 4,40. N: 6.
it. Actual value C: 57.85. H: 4,32. N: t3
.. 11゜Example 5 Synthesis of N-cyclopropyl-2,3,4゜-trifluoroaniline Acetamide (Example 4) 1 g of 950# was poured into a mixture of 30 dl of 10% caustic soda solution and 10 dl of ethanol. b) Washed with water, dried over anhydrous sodium sulfate, and concentrated to obtain 0.63 g of the desired product as a pale brown oil. Example 6 Diethyl N-cyclopropyl-N-(2,
Synthesis of 3,4,-trifluorophenyl) aminomethylene malonate Aniline compound (Example 5) 0.6SF and diethyl ethoxymethylene malonate 1. Mix 150-190
Stirred at ℃ for 1.5 hours. After cooling, the product was purified by flash column (0-bek4nan-ethyl acetate) to obtain the desired product 0.66SF as a colorless oil. Example 7 1 chill 1-cyclopropyl-6°7.8-
Trifluoro-1,4-dihydro-4-4 key 71
Iゝ/-Q-1+Repo Honsylate Synthetic Maroney (
Example 5 Add 5541 ng to 4 g of polyphosphoric acid and stir at 120 to 130°C for 1 hour. Cold, add ice water, extract with chloroform, dry and concentrate with anhydrous sodium sulfate, purify the residue using a flash column (1:3, ethyl acetate: methylene chloride), and recrystallize from acetonitrile to obtain 230 ml of the desired product as colorless needles. /j. Elemental analysis: Calculated value (C+ s l-1t z F3NO
3), C: 57.88. l-1: 3. '89.
N: 4,50°Actual measurement C: 57.68. H: 3.74. N: 4.
50゜Example 8 Synthesis of 1-cyclopropyl-6,8-difluoro-1,4dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid (carboxylate) Example 7) 206Il+y and N-methylpiperazine were added to 200 m9 dimethyl sulfoxide (DMSO) 5- and stirred at 90-100°C for 2 hours. After concentration, the residue was dissolved in 60 td of chloroform, the chloroform layer was washed with aqueous potassium carbonate solution A3 and water, dried with anhydrous sodium sulfate, concentrated, 101 dl of 1N caustic soda was added to the resulting residue, and the mixture was stirred on a boiling water bath for 1 hour. Insoluble materials were removed by filtration, and the filtrate was adjusted to I)H7 with acetic acid and concentrated. The residue was subjected to high performance liquid chromatography (Ol) S-C'+
a, 5.4% ammonia water: methanol-5=9
It was fractionated using a silica gel column (from chloroform to chloroform: methanol: aqueous ammonia = 10: 10.: 3),
Recrystallized from methanol to obtain 63 mg of colorless needle crystals.
Obtained 1c0, melting point 220-221°C. Elemental analysis: Calculated value (C+ s H+ sF2 N303
), C: 59.50. H: 5.27. N:
11,56° Actual measurement value C: 59.24. 1: 5.21. N:
11,47 Example 9 1-Cyclopropyl-6,8-difluoro-7biperazinyl-4-oxoquinoline-3-
Synthesis of carboxylic acid 30 tng of carboxylate compound (Example 7) and 40 tng of piperazine were added to DMSold and heated at 90 to 100°C.
Stir for hours. Thereafter, it was treated in the same manner as in Example 8, and recrystallized from methanol to obtain a cream-colored needle-like object 8'm.
I got l'Fr. Melting point: 270°C ~ (decomposition). Elemental analysis: Calculated value (C+ 78+ 7 F'2 Nz
03 >, C: 58.45. H: 4.91. N
: 12.03°Actual measurement value C: 58.37. H: 4.89. N: 12
, 20° Test Example 1 The antibacterial spectrum antibacterial test was conducted according to the method specified by the Japanese Society of Chemotherapy. The results are shown in the table below. - L \ Kodushichi ^ Test Example 2 Effect on mouse systemic infection I of 5 mice per group
CR mice were intraperitoneally injected with Escherichia coli (E. coli).
ML 4707) was injected at a rate of 4.9 xioa bacteria/mouse, and 1 hour later, 7 doses of the drug were each administered by tube.
From the curve of drug dose and survival rate, fit (E[)50) was determined so that 50% of the animals would survive and be cured. Table 2 shows the results. The compound of Example 8 of the present invention was about 6 times more active than ofloxatin and about 33 times more active than norfloxatin. Table 2 (llly/d) ED50 (ll+9/Kg) Example 8 Compound 0.025 0.15 Ofloxatin 0.05 0.90 Norcloxatin 0.05 5.0 Procedure': 4 city official papers (voluntary) 1982 July 30th, Mr. Manabu Shiga, Commissioner of the Patent Office1, Indication of the case, 1981, Special Patent Application No. 2325602, Name of the invention, Quinolone Carboxylic Acid Derivatives3, Relationship with the person making the amendment, Address of the patent applicant 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo Name (139) Kyorin Seisou Co., Ltd. 4, Agent address 16-101 Kanda Kita Jorimono-cho, Chiyoda-ku, Tokyo 101
English Building 3rd floor 6, Description subject to amendment 1, Title of the invention Quinolone carboxylic acid derivative 2, Claims (1) General formula (wherein, R is hydrogen, methyl or p-aminopendel; Y is chlorine, fluorine or methyl), their hydrates and their salts. (In the formula, RI is hydrogen or lower alkyl, X is halogen, Y is chlorine, fluorine or methyl) Claims characterized in that compounds represented by '!l), which represent pendel, are condensed, and further hydrolyzed when R1 is lower alkyl, or further reduced when R2 is p-nitropendel. 2. A method for producing a compound represented by the general formula (I), a hydrate thereof, and a salt thereof as described in item 1. 3. Detailed Description of the Invention The present invention provides novel quinolone carboxylic acid derivatives represented by the general formula (wherein R represents hydrogen, methyl or p-aminopendel, and Y represents chlorine, fluorine or methyl), and salts thereof. , its production method, and its use as an antibacterial agent. The compound of the present invention was newly synthesized by the present inventors,
It has been discovered that it not only has in vitro antibacterial activity over a wider range of Durham-positive and -negative bacteria and is effective at lower doses than the prior art quinolone carboxylic acids, but also has the property of being better absorbed in animals. This led to the present invention. Next, a method for producing the compound of the present invention will be explained. (In the formula, X represents halogen, R1 represents hydrogen or lower alkyl, R2 represents hydrogen, methyl, p-benzyl, or p-aminopendel, and Y and R are the same as above.) That is, formula CII ] The compound represented by the formula [II[
] By reacting with a compound represented by formula [1]
The compound of the present invention represented by is synthesized. However, the formula [1
When R2 is a p-nitropendel compound in [1], the reaction product with the compound represented by formula [1] is reduced according to a conventional method to convert the nitro group to an amino group to obtain the compound of the present invention. I can do it. In addition, in the case of a compound of the formula [, I[] in which R1 is lower alkyl, the reaction product with the compound represented by the formula [I[] is hydrolyzed according to a conventional method to convert nistyl into a carboxylic acid. It can be made into an invention compound. The reaction between the compound represented by formula [II] and the compound represented by formula [111] can be carried out in the absence of a solvent or in the presence of water, alcohols, dimethylbormamide (DMF), dimethyl sulfoxide (DIv'l5O), hexamethylphosphorus amide, pyridine. , in the presence of a polar solvent such as picoline 0
Let's do it. The reaction temperature is room temperature to 200°C, preferably 60°C to
The temperature is appropriately selected within the range of 160°C. For more details, use the formula [
1 [] and 2 to 5 times the molar amount of the formula [111
] in 2 to 10 times the volume of the above solvent,
Heating at 60 to 120°C for 1 to several hours is preferred. Further, the compound represented by the formula [II can be converted into a salt thereof according to a conventional method, if desired. Examples of salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid; salts with organic acids such as methanesulfonic acid, lactic acid, and acetic acid; and carboxylic acid salts such as sodium W, potassium salt, magnesium salt, nocorcium salt, and aluminum salt. Examples include salt, cerium salt, rim salt, Kobal] to salt-1 sea bream salt, iron salt, zinc salt, silver salt, and the like. The compound represented by the general formula [11], which is the starting material of the present invention, is also a new compound, and can be synthesized, for example, by the route shown below. 2, which serves as the starting compound;
3,4,5-Tetrafluoronitrobenzene is known and can be produced, for example, by nitrating 1,2,3°4-detrafluorobenzene (Tetrabed).
Ron, 23.4719°1967). The compound represented by the general formula [I] of the present invention, its hydrates, and its salts exhibit excellent antibacterial properties against Gram-negative bacteria and Durham-positive bacteria, and are not easily absorbed when used as pharmaceuticals. Hope it's good. For this purpose, absorbability is enhanced by attaching a lower alkyl group or p-aminopendel group to piperazine, or by introducing a halogen group at the 8-position. The drug according to the present invention may be administered in the form and route of administration to animals and plants as a conventional pharmaceutical, but may be administered in the form and route well known in the pharmaceutical industry, namely, tablets, capsules, powders, ointments, injections, and eye drops. Applicable to drugs, crude drugs, etc. Next, the method for producing the compound of the present invention and its antibacterial properties will be explained in detail with examples. Example 1 Synthesis of 2-cyclopropylamino-3,4,5-trifluoronitrobenzene 2.3,4,5-tetrafluoronitrobenzene 3.1
9 toluene 20a! ! Cyclopropylamine 2 in solution
A 5-solution of - in toluene was added at 10°C or lower, and the mixture was stirred at room temperature for 1 hour. 50iIIIi of benzene in the reaction solution! Add 20 m of ice water and separate the organic layer, wash with water, dry anhydrous mirabilite,
After concentration under reduced pressure, the residue was purified using a flash column to obtain the target products 2,559 and 4-cyclopropylamino-2,
3,51-lifluoronitrobenzene was isolated. Example 2 2-(N-cyclopropyl)acetamide-3°4.5
Synthesis of -1-lifluorodi-1-lobenzene cyclopropylamino compound (Example 1'') 0.9 g of acetic anhydride 10
#Ii! When two drops of concentrated sulfuric acid are added to the solution, heat is generated and the orange color of the solution disappears instantly. After 5 minutes, the reaction solution is poured into ice-potassium carbonate aqueous solution and extracted with ether. The ether layer was washed with red water, dried over anhydrous sodium sulfate, the solvent was distilled off, and the residue was recrystallized from hexanoyl to obtain 0.868 g of the desired product. Pale yellow-green prismatic crystals, melting point 91-92°C. Elemental analysis: C1189F3 N203g1 calculation 1a C
: 48,19, H: 3,31. N: 10
.. 21 actual measurement value C: 48,53, T1: 3,3
0. N: 10.31 Example 3 2-(N-cyclopropyl)acetamide-3°4.5
-Synthetic acetyl form of triflumeroaniline (Example 2) 0.8 g was added to 4 ml of ethanol.
Dissolved in a mixed solution of 0Id and acetic acid 20-, 10% P
Add d/C20 (lI#) and perform hydrogenation at normal pressure for 50 minutes. After filtering the reaction solution, concentrate under reduced pressure, dissolve the residue in 100Id of chloroform, wash sequentially with an aqueous solution of sodium bicarbonate and water, dry with anhydrous sodium sulfate, and evaporate the solvent. The residue removed by τ1q is recrystallized from ethanol to obtain 0.534 g of the target product. Light brown prismatic crystals, melting point 171-173°C. Elemental analysis: C11f'u Fs NZ 03 calculated value
C: 54.10, H: 4.54. N: 1
1.47 Actual value C: 54.26, H: 4,5
7. N: 11.50 Example 4 Synthesis of N-(2,3,4-trifluorophenyl)-N-cyclopropylace1-amide Aniline compound (Example 3) 1.26 g was added to 10 td of anhydrous dimethylformamide (DMF). In addition, 0.92y of freshly distilled amyl nitrite was added dropwise to an anhydrous DMF5IrR solution at 60-65°C for 20 minutes. After cold addition, 150Id of ether was added, and the organic layer was washed successively with water, dilute hydrochloric acid, and water, dried with anhydrous sodium sulfate, concentrated, and the residue was purified by flash column (2:3.n-hexane:ethyl acetate). 0.95 g of the target product was obtained. Recrystallization from n-hexane yields colorless sword-shaped crystals with a melting point of 99-100°C. Elemental analysis: Cu HIOF3 N20 calculation value C:
57.64, )(: 4.40. N: 6.1
1 actual measurement 1aC: 57.85, 1-(: 4.32.
N: 6.11 Example 5 Synthesis of N-cyclopropyl-2,3,4-trifluoroaniline 950 mg of acetamide compound (Example 4) was added to a mixture of 30 m of 10% caustic soda solution and 1 ml of ethanol (80 ~ Stirred at 90°C for 4 hours.After 6 hours, needle extraction was performed, washed with water, anhydrous sodium sulfate was dried and concentrated, and the desired product was obtained as a light brown oil with 0.0%.
63 SF was obtained. Example 6 Synthesis of diethyl N-cyclopropyl-N-(2,3゜4-trifulAO]1-nyl)aminomethylene malonate Aniline (Example 5) 0.6 g and diethyl ethoxymethylene malonate Mix 1.04g and 150
Stirred at ~160°C for 1.5 hours. After cooling, it was purified by flash column (n-hexane-ethyl acetate),
A colorless oily target product of 0.665F was obtained. Example 7 Synthesis of ethyl 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate Malonate compound (Example 6) 554 mg was mixed with polyphosphoric acid 4
g and stirred at 120 to 130°C for 1 hour. Cold, add ice water, extract with chloroform, dry anhydrous sodium sulfate, concentrate, and transfer the residue to a Flood 1 column (1:3, ethyl acetate:
The product was purified using methylene chloride) and recrystallized from acetonitrile to obtain the desired product 23GIAI in the form of colorless needles. Melting point 1
75-176℃ Elemental analysis: C+s H+2Fa NO
3 play calculation value C: 57.88. 1: 3,89.
N: 4.50 actual value C: 57,68. l-
1: 3.74. N: 4.50 Example 8 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4-methyl-1-perazinyl)-4-
Synthesis of oxoquinoline-3-carboxylic acid [carboxylate] monolithic (Example 7) 206iy and N-methylpiperazine 20 (m is dimethylsulfoxide
) 5d and stirred at 90 to 100°C for 2 hours. After concentration, the residue was dissolved in 60 ml of chloroform, the chloroform layer was washed with an aqueous potassium carbonate solution and water, and after drying with anhydrous sodium sulfate, 10 d of 1N caustic soda was added to the resulting residue and stirred on a boiling water bath for 1 hour. Insoluble matters were removed by filtration, and the filtrate was adjusted to pH 7 with acetic acid and concentrated. The residue is removed by high-speed liquid O-mography (ODS-CI+,
5.4% ammonia water: methanol-5=95-30:
silica gel column (from chloroform to chloroform:methanol:concentrated ammonia water).
10:10:3) and recrystallized from methanol to obtain the target product G3tas in the form of colorless shingles. Melting point: 220-221°C. Elemental analysis: Cva l-ll9FZ N303 calculated value C: 59.50. 1: 5.27. N:
11,56 Actual measurement 111i C: 59,24. )−
on 5.21. N: 11,47 Example 9 1-cyclopropyl-6,8-difluAO-7-(1-
Synthesis of carboxylate (Example 7) 30mg of piperazinyl)-4-71xoquinoline-3-carboxylic acid and 40IRg of piperazine were added to DMSOI to give 90.
The mixture was stirred at 0°C for 1 hour. Thereafter, it was treated in the same manner as in Example 8 and recrystallized from methanol to obtain 8111 g of the desired product in the form of cream-colored needle-like crystals. Melting point: 270°C ~ (decomposition). Elemental analysis: C+r I"+r Fz Nz Os Calculated value C: 58.45. l-1: 4.91. N
: 12.03 actual measurement value C: 58,37. Part 1:
4,89. N: 12.20 Example 10 Synthesis of ethyl 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(1-piperazinyl)-4-A xoquinoline-3-carboxylate Perazine 1.13 g of dimethyl sulfoxide 15d
0.82 g of carboxylate compound (Example 7) was added to the solution, and the mixture was stirred at 60° C. for 2 hours. Cold welding, add 200ml of chloroform to the reaction solution, wash with potassium carbonate aqueous solution,
% hydrochloric acid, and the extract was diluted with sodium hydroxide aqueous solution.
I-110-11 was quickly extracted with chloroborm. The chloroform layer was washed with water, dried over anhydrous sodium sulfate, concentrated until crystals began to precipitate, added hot water, cooled, and the precipitated crystals were collected by filtration to obtain a colorless 11-shaped target product (1.87 g). Melting point 211-212℃ Elemental analysis: C4H21F2 N30s Calculated value C: 13 (1,47, H: 5.61,
N: 11,13 Actual value G: 60.50, T1: 5.50, N: 11,14 Example 11 1-Cyclopropyl-6,8-difluoro-1,4-dihydro-1-(1- Synthesis of (piperazinyl)-4-A xoquinoline-3-carboxylic acid 0.879 g of ethyl carboxylate (Example 10) was added to 20 d of 1N aqueous sodium hydroxide solution and stirred at 100°C for 1 hour. After cooling, the reaction solution was neutralized with acetic acid, the precipitate was collected by filtration, and recrystallized from methanol to obtain colorless prism crystals of the target products o and eo g. Melting point 270-270.5℃ (decomposition) Elemental analysis: Car H+r F2 N303 ・
M)-1z O calculated value C: 57.71, )-1
: 4.99, N: 11.88 Actual value G:
57.85, It: 11.92, N7
11. &8 Test Example 1 The antibacterial spectrum antibacterial test was conducted according to the method specified by the Kuchiju Chemotherapy Society. The results are shown in the table below. Test Example 2 Effect on Mouse Systemic Infection Using 5 IOR mice per group, Escherichia coli (E,
coli ML 4707) at 4.9 x 106 cells/mouse or Pseudomonas aeruginosa (P, aeruoinosa II
[)1210) was injected at 3.5X 105 mice/mouse, and 1 hour later, 7 doses of the drug were administered via the tube tube. According to the curve of drug dose and survival rate, 50% of the animals escaped death and were cured. I bought a ff1 (ED50). Table 2 shows the results. Compounds of Example 8 and Example 9 of the present invention exhibited extremely superior infection prevention effects compared to ciprofloxacin used as a control. -J ~ Ge5 Neyama Masamari; (Hakko) 1981 iT: November 29 [1 Special If Agency Director Shi rq Manabu Tono III Japanese 1958 Special ffi'FIlfi ff+232
560Q2, Title of the invention: Quinolone carboxylic acid induction tree 3, Relationship with the case of the person making the amendment Patent applicant address: 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo Name (139) Kenho Kyorin 2, J (Company 4. Agent address: 16 Kitajomono-cho, Chiyo, Tokyo [Kami Ll, I1 Ward] 101 Eiji Hill, 3rd floor, 5. Number of inventions to be covered increased due to amendment: 2 6. Subject of amendment: IV floor, 117B Zenbumi 9 ■ Exit 1 , Name of the invention quinol-carboxylic acid derivative 2, !ltera crystal'1i blue j-poor range (in the formula: Y LL li
Compounds represented by i, fluoride or methyl, and their hydrates and salts. (In the formula, R' is hydrogen or halogen, Y is chlorine, F, z4/j is methyl) and the general formula (wherein, R is Hydrogen, methyl, p-l-D not\zyl still (J indicating good-aminobenzyl) Compound 4 condensed U, 1〈1 or lower 〒1 in case of argyl GJ further hydrolyzed J? , or 1 is 1
〉-21...Lobenzil's lifting platform (general formula C described in No.
A method for producing a hydrate of the compound I) and a salt thereof. (3) General formula n (wherein, R1 is hydrogen or lower alkyl, Y is Hanawa;
1)-Nitropenzyl halide is condensed to a compound represented by fluorine or methyl (representing fluorine or methane), and if necessary, the ester is hydrolyzed. It is characterized by J. General formula (■), -. (In the formula, R represents 1)-aminobenzyl and Y represents chlorine, fluorine or methyl) and its hydrate -1ρσ and its salt I! iU 3+17 nono method. /l) General formula (wherein, R1 is hydrogen or lower fulkyl, Y

【よ塩素、
弗素また(よメーf−ルを示づ)(゛表わされる化合物
にメチル化剤を作用し、要覆ればエステルを加水分解す
ることを特徴とする。 (式中、R(、エステルを、Yは塩点、弗素j;たはメ
チルを示1)で表わされる化合物およびその水和物並び
にその塩の製造方法。 3、発明の詳細な説明 本発明1よ一般式 (式中、Rは水素、メチル、1〕−二1〜口ベンジルJ
、たf:L lアミノペンシルを、Yは稿本、弗素よた
(よメチルを示’!l’ > ′c表わされる新規な−
にノロンカルボン酸誘導体、その塩、その製造方法、お
よびての抗菌剤どしての用途に関りる。 本発明の化合物は、本発明者らにより新規に合成され、
先行技術によるキノ0ンノjルボンMJ、すし試射ji
内の抗菌活性がダラーX陽t/l並びに陰11菌ど広範
囲に及び且つ11(川54−c 9)J宋を発揮lるば
かり’C’ <K < 、動物に於て吸収が良好な特性
をイJJ−る事が発見され、本発明に至ったのである。 次に本発明化合物のツノ造方法についで説明りる。 (式中、Xはハロゲンを、R’+、r7i’、3・−ま
たは低級アルキル、Rは水素、メチル、11−二1〜口
ベンジル、または1)−アミノベンジルを示し、Yは前
記に同じ) ずなわら、式[IF ]で表わされる化i′’i物をJ
([I[1]で表わされる化合物ど反応さけることによ
り式[I ] −c−表わされる本発明化合物が合成さ
れる。ただし式[nl]でRがp−二1−[1ヘンシル
の化合物の場合1=を式[I【]で表4′ノされる化合
[1基をアミノ基に変換して本発明化合物にする事が出
来る。また式[n]でR1が低級アルキルの化合物の場
合は式[1[1]で表わされる化合物との反応成績体を
常法に従−)で加水分解して1スプルをノJルボン酸に
変換して本発明化合物にする事が出来る。 また、式CI)rRがp−アミノベンジルの化合物は式
(I)でRが水素の化合物またはそのニスデル(IV) (式中、RIは水素、メチル、p−ニトロベンジルまた
はII−アミノベンジルを示す)とp−二1−口ペンジ
ルハライドを反応さけ、式(I)でRが11−二1へロ
ベンジルの化合物又はそのニス−グルとし、前記同様ニ
トロ基をアミノ基に還元し、要すればエステルを加水分
jl?することによっても合成することが出)1コる。 また、式〔1〕でRがメチルの化合物は式(IV)の化
合物にメチル化剤を171用さL!、ilればエステル
を加水分解することによっても合成することが出来る。 式[I[]で表わされる化合物とj([ITI]で表わ
される化合物の反応は熱溶’j’J −i +lつるい
は水、アルコール類、ジメチルホルムアミド(D M 
F >、ジメーfルスルボー1シト(D、MSO)、ヘ
キサメチルホスポリツクアミド、ピリジン、ビロリンの
ような極性溶媒の存在下で行なう。反応福晶度は室温〜
200℃、りYましく(よ60・〜・160℃の範囲で
適当に選択される。更に訂しくは式「II]で表わされ
る化合物と2〜54B ’cルの式[I[1]で表わさ
れる化合物を2〜1018容の前記溶媒中で、60〜1
20 ”Cに1〜数時間加熱するのが好適である。また
、Rがp−ニトロベンジルである化合物の1)−アミノ
ペンシルである化合物への還元は、例えばパラジウム炭
、白金等の触媒下、水素気流中で・の接触32元または
鉄、錫、亜鉛あるいはfクン等の金属Jたはぞれらの!
;蟲を用いる金属)至元等、通常良く知られたノ)法で
実施することが出来る。 また1式〔1v〕の化合物とp−二1〜(]ベンジルハ
ライド、例えばクロライド、ブロー、フイ1−との反応
は適当な溶媒中でIBH1!を剤例えばトリエヂルj′
ミン、炭酸カリ等の存在下に室温から使用した)8媒の
沸点の温度で実施することが出来る。 更によIζ、式(IV)の化合物のメチル化(ま例えば
−3−化メチル、央化メチル、ジメルl1jt n’j
あるいはホルマリンどギ1lftまたは;7元剤等の一
般に良く知られたメチル化剤で通路よく用いられる条1
′1に(実/ll!!することが出来る。 11に式[丁]で表わされる化合物は所望ならば、その
塩に名;法に従って変換する事が出来る。 」福とじCは例えば塩酸、t+bt酸、燐酸等の1ハ(
機酸どの塩、メタンスルホン酸、乳酸、西1酸簀の右1
幾酸どの122、あるいはカルボンII?のナトリウム
j昌、カリウム塩、マグネシウム塩、カルシウムjO、
アルミ−ラム」ム、セリウム塩、クロム1+Δ、:」パ
ル1〜塩、銅塩、鉄塩、亜鉛塩、銀1λ晶、ニックルー
B等が挙げられる。 本発明の出発物質である一般式[■]で表わされる化合
物もまた、新規化合物であり、例えば次に示されるよう
なルー1−で合成りる事が出来る。出発化合物となる2
、3,4.5−テトラノルAロニI−ロベンUンは公知
であり、例えば1.2,3゜4−デl−ラフルAロベン
ゼンを二1・1」化して製造りることがで、さる( T
 eLl゛allOLIl’oll、 23.4719
゜196フイ1− ) 。 [ [ 本発明の一般式[I]で表わされる化合物Jjよびその
水和物並びにその塩はグラム陰性菌およびダラム陽性菌
に対して優れた抗菌特性を示り。V、桑品として使用さ
れる場合吸収が良好なことが望まれる。ぞの為に、8位
にハ「1グン基を導入づることにより吸収性を高めたも
のである。本発明にか・る桑物は通常の医薬品としての
大または動植物への投与形態J5よび経路によるが、従
来薬学的に良く知られた形態おJ:び経路叩ら、錠剤、
カプセル、散剤、軟吉、注射液、点111N剤、生薬等
に適用される。 次に本発明の化合物のV漬方法およびその抗F:i特性
を実施例をもってh1細に説明リイ)。 実施例1 2−シフ[1プロピルアミノ−++ 、4 + 5 ’
−l・リーノルΔ[]]二1−〇ベンゼの合成 2 、3 、4 、5−アトラフルΔ【二1−トD /
\ンゼン3.1Jの1−ルエン20m1溶’61にシク
ロプロピルアミン2mβのトルエン5#Ii!溶液を1
0℃以下で加え、〒渇1助間攪拌した。反応溶液にベン
ぎン507および氷水20#112を加えず4Ia層を
分取し、4(洗、無水芒硝乾燥、減圧濃縮後、残渣をノ
ラツシコカラムにより精製し、目的物2 、 ’、+ 
5gj3J:び11−シクロプロピルアミノ−21J 
+ J−l−リフルAロ二1〜L1ヘンじンを単離した
。 実施例2 2−(N−シクロプ1]ビル)アレドアミドー3゜4.
5−1〜リフルオロニトロベンゼンの合成シクロプロピ
ルアミノ体(実施例1)0.9!1の無水酢酸10Il
溶液に濶硫酸を2滴加えると発熱し、溶液のオレンジ色
が瞬時にd1j失りる。5分後、反応溶液を氷−炭酸カ
リ水溶液に注ぎ、エーテルで抽出する。1−チル層を希
IAf 6M、水で洗い、ツ1((水芒哨乾燥後溶媒を
留去し、残渣をヘギ1ナンから再結晶して目的物0.8
08 qを得る。 淡貞゛1縁色プリズム品、融点91〜92”C。 元素分析: Cu t−1s l”3 N203iil
紳(lrl C:48,19 、1」:3,31. N
 : 10,21実、(111111C: 48.53
 、 l−1: 3..30. N : 10.31実
施例;3 2−(N−シフ「Jプ[」ビル)アレドアミド−3゜4
、!i−i〜リフルAロアニリンの合成アセチル体(実
施例2>o、agを1−タノール407 j3J−’O
’ )It 酸20mQのiIL合ン容a謎にンd解し
、10%P d ′(’、、 200myを加え50分
間常圧で水素添加をtj’j ’T)。反応液を濾過後
、減1丁謂縮し残渣をり++ n ホルム1001II
LニFB’AY LjJ炭醇ソー ’J 水fJ液、水
(’ M+’i次洗い1,111−水芒硝で乾燥し溶媒
留去してi’=? l)れる残)】11をLタノールか
ら出結晶しC目的1勿0 、 ’、1 ’、)4 X7
をtlする。淡褐色ブリスム晶、融点171へ、173
℃1゜ 元素分析: C1l t−In F3 N2O3訓算餡
 C: 54,10 ; l・l : 4.54. N
 : 14.47実測値 C: 54.26 、 H:
 4.57. N : 11.:i。 実施例4 N −(2,3,4−トリフルAロフ「−ル) 、−N
 −シクロプロピルアセトアミドの合成 72921本(実施例3 ) L269を無水シメチJ
レホルムアミド(DMF)10mQに1川え、釘iたに
蒸留した亜硝酸アミル0.9哩の無水D M F 5 
mQ溶液中に60〜65℃で20分間で滴下しl、:。 冷1受、1−−jル150 tr認を加え、有1幾日を
水、希塩酸Jjにび水で順次洗>7’ シ、無水芒硝乾
燥’、、−′C澗縞し、残)青を一ノラツシjカラム(
2: J + ’l−”\キリン:lit酸1デル)に
」、す1h興して目的4′I+0.95gG得た。n−
へキリンから再結晶りると、無色iI状fi’:i品、
融点99〜100℃となる。 元素分析: Co Ll+o r: Nz 0IiI算
値 C: 57.GA 、 N : 4.40.N :
 6.11実測1aC: 57.85 、 l−l :
 4.32. i’J : (i、N実施例5 N−シフ1コシUJビル−2,3,41−リフルア D
アニリンの合成 アレ1〜アミド休(実施例4 ) 950I++yを1
0%苛性ソータ液30mQ I+) J:び]−タノー
ル101nQの1昆合i+Vに加え80・〜・90°C
で411.!7間撹拌した。冷接ニーーiル抽出し水洗
、無水芒硝乾燥して謂縮し、淡出色油状の目的物0.6
39を(’7k。 実施例6 ジLデル N、−シフ1]プ[二]ピル−N−〈2,3
゜4−トリフルAロフ」−ニル)アミノメチレンマし】
ネー1への合成 71ニリン体〈実施例5 ) 0.69おj、び1−ト
キシメチレンζノ[lン醇ジエチル+、o4gを混合し
1!+O□” 160’C(1,、’+ II:f l
!D Its J’F シた。冷五〇後、フラッジ−1
カラム(11−ヘキサン−酢酸エチル)により昂製しく
、無色油状の目的物(lJ6≦1を111k。 Jミ施例7 ■−デル 1−シクロプロピル−C)、7.8−1〜リ
フルJ−1’l−1,4−ジヒドll−4−/1キソキ
ノリン−3−カルボキシレー1〜の合成 マロネー1一体〈実施例6) 554In!jをポリリ
ン酸4Uに加え、 12(i= 130”C−(111
)間IX2拌した。 冷接、氷水を加えクロロボルム抽出し烈水芒硝乾燥後淵
縮し、残)古をフラッシコ力ラム(1:3、酢酸エチル
:塩化メチレン)にJ、り精製しアL!1・二l−リル
から再結晶して2j1(色11状品の目的物236rn
:lを賀た。 融点175−’17G”Q元4;分(1
1: Cus 1112 F3 NO3泪い埴 C: 
57.88. H: 3.89. N : 4,50実
測値 C: 57.68. El :3.74. N 
: 4.50実施例8 1−シクロプロピル−0,8−ジフル>1o−1,4−
シじドロー7−(4−メチル−1−ビベ0ノシェル)−
4−オキソキノリン−3−カルボンnI2の合成カルボ
ギシレート体〈実施例7)200mgお上びN−メチル
ピペラジン200mgをジメチルスルホキシド(DMS
O)!sn&に加え90〜100°Cc2 +1?間攪
拌した。)R綿筒、残漬をり[IL1ボルムGOtrd
!に溶解し、クロロホルム層を炭酸カリ水溶液お上ひ水
C洗い、無水芒硝乾燥後、:Bシ縮して1”1られる残
)白に1Ni’j″i性ソーグ10 nrQをj)■え
ン月:脇水iii −IZ−c111F+ tril 
II打した。不id物(H,a、iH去し、−R/I々
 を 酎 配 −(1’ l−17tこ Δ囚 整 し
 C)閂 縮 し ノご 。 残:?j ’a’ It’%速液体り1−171へグラ
ノィ−(OI) 5−C1ε、5.4%アンIニア水:
メタノールー5:()5・〜□30ニア0)ににり分取
し、さらにシリカゲルツノラム〈クロに]ホルムからり
[’l 1丁1ホルム:メタノール:濶アン七ニ)7水
−10:10:3)にJ、り粘製し、メタノールから再
結晶して無色針状晶の「1的’161 G t’l m
gを)−ノだ。)、融点220〜221”C0元i)・
9分iji : Cu81(+9F2 N30361 
ξン11自 C: 59.50. II : 5.27
. N : 11.56実測舶 C: 59.24. 
II : 5.21. N : +4,47実/#例9 1−シフIJ ’71−1ビル−6,8−シーツルーA
−Ul −7−(L−ビベラシール)−11−4キソニ
1ノリン−3−カルボン酸の合成 カル小キシレ−1−141(実/11!!例7 ) 3
0nrg t3 J: Uビベ−シシン4 Q mgを
L)MSOlmffに加工90〜100℃で1時間攪拌
した。以後、実施例8と同(];に処理し、メタノール
から再結晶してり1ノー八邑の釦状品の目的物(3mg
を17だ。 融点270℃〜(分解)。 元本分(1j : CIF 11+r Fz N20B
911′ン 11fJ C: 58,45. l−l 
: 4.91. N : 12.03実イ則イlI′i
 C: 58.37. l−1: 4,80. N :
 +2.20実施例10 1−シクI’lプ【」ビル−6,8−ジフルJII −
1,/1−ジヒドロ−7〜(1−ピペラジニル)−4−
71キソ−1−プリン−3−カルボン酸エヂルの合成 ピペラジンi、+37のシメfルスルホ4−シ1〜15
mf!溶液にカルボキシレー8f本(実施例7)0.8
29を加え、60′Cで2時間撹拌した。冷接、反応液
にクロ[」ボルム200 l逆を加え、炭酸カリウム水
溶液で洗浄後1%塩酸で抽出し、抽出液を水酸化ナトリ
ウム水溶液でPI−110−44どして素早くクロロホ
ルムで抽出した。少し1[Jホル11府を水洗、無水芒
硝(゛乾燥後、結晶が析出しはじめるまで濃縮して熱ア
セ1〜ンを加え、冷接、析出品を濾取し無色11状品の
目的物0.87 gを111 ノこ 、、、 J 点 
211〜212℃元Xj>41’+ : Cf9 1−
121 F2 N3 03:1算11& C:Go、4
7 、 H: 5.G1 、 N : 11.13実測
値 C: 60.50 、 H: 5.50 、 N 
: IL14実施例11 1−シクロプロピル〜6,8−ジフルオロ−1,4〜ジ
ヒドrj−7−(1−ピペラジニル)−4−オキソキノ
リン−3−カルボン0プの合成 カルボン酸エチル体(実施例10)0.87i7を1N
水酸化ナトリウム水溶液20mQに加え、100°G”
CI詩間撹拌した。冷接、反応液を酢酸C中和してJl
i出物を濾取し、メタノールから再11、+4 Ll 
(Jp、l、 (Qア1.J 、7” A !% O[
1約物4%水和物、0.60丁I+:j+′71こ。融
点270〜270.5’C(分解)元索分41i : 
C+r I−1+r F2 N303 ・MHz 0r
it U) lfj C:57.71 、 I−1: 
4.99. N:11.88実測fla C:57.8
5 、 H: 4.92 、 N : N、88実施例
゛12 1−シフ【」プロピル−6,8−ジフルオロ−1,4−
ジヒドn −4−:4 :lソ〜7−(1−ビl\レジ
ニル) 、−3−ギノリンカルボン酸・1zl塩の合成 1−シクロプロピル−6,8−ジフル4 a−・1,4
−ジヒドロ−4−′Aキソー7〜(1−ピペラジニル)
=3−キノリンカルボン酸1.09を’d* J2.i
Wj 20m!’にどかし、濃縮後、残渣をメタノール
(1: i、 io。 d)から再結晶して無色剣状納品の[j約物0.90 
gを得た。 融点 300℃(分と)Y)元素分イ/F
 : C++ +−117F2 N! Os ・l−I
 Cf泪騨値 C:52゜93 、 l−f : 4.
TO、N : 10.89実測値 C: 52,97 
、 H: 4.GG 、 N : 10,90実施例1
3 1−シフロブ1]ピル−6,8−ジノル/1゛ロー1.
4−ジヒドロ−7−(4−メチル−1−ピペラジニル)
−4−′;A−1−ソー3−キノリンカルボン酸・l福
酸j嘉の合成 1−シフロブ[Iビル−G、8−シフルア1’ [1〜
1,4−ジヒドロ−7−(4−メチル−1−ピペラジニ
ル)−4−オキソ−3−4−ノリンノJルボンnプ H
7m、qを実施例12と同様に処理し、水およびメタノ
ールから順次再結晶してフ!!(色11状品の目的物(
1水和物) 12318グを(qだ。 融点266℃(
ブ2解)元素分析: Cm l−1+a Fz N30
B ・l−lCf ・l−120計”C?1ifi C
:51.74 、l−1:5.’30 、N : 10
.0G実測1ifi C:52.03 、 ti : 
5.20 、 N : 10.20実施例14 1−シフロブ[1ビル−6,8−ジフルオロ−1,4−
ジじトD −7” (4−(Il−二1−ロベンジル)
−1−ピペラジニル)−4,−オキソ−3−=1−ノリ
ンカルボン醸の合成 1−シフロブ【−1ビル−6,8−シフルア1[]−]
1.4−ジヒド1]−4−オキシー7(1−ピペラジニ
ル)−3−二1−ノリンノJルボン5p、 900 N
3をジメチルホルムアミド([)lvlF)20mに溶
解し、j)−二トロベンジル7 II ?Il” 84
0m9 Jj にひ1−リエチレンアミン0.4dを加
え、80〜90℃で10時I7!1攪拌した。反応:I
lを濃縮後、残渣に水を加えて析出物を濾取し、D )
N4 F−エタノールから再結晶して、褐色結晶の目的
物(Z水[1物) 845 mylを(9た。 融点195へ、197℃ 元素分析: C24N22 F2 N40: ・j41
40計算直 C: 58.77 、 H: 4.6G 
、N : IL42実1ltNij7 C:58,83
 、 l−1: 4.48 、 N : N、35実施
例15 714−(1)−アミノベンジル)−1−ピペラジニル
)〜1−1−シフロブロピルー6−ジフル、40−1.
4−ジヒドロ−4−オキソ−3−キノリンカルボンR)
の合成 1−シクロプロピル−6,8−ジノルメロ−1,4−ジ
ヒドロ−7−(4−(++−+−−ロベンジル)−1−
ピペラジニル)・4−Aキラー3−二1ニノリンカルボ
ン酸く月水和物) 800m!7を氷酢酸20mQにm
 lf”?し、10?6 lid/ CI SOIII
gt IJII ニー’(至濡テIQ li’ L <
’;がら水糸ガス200mf!/!、吸収させた。反応
液4濾過後、濾液に氷水を加え、水酸化すトリウム水溶
)1りで中和してクロロホルムで抽出し、無水芒硝C乾
燥して濃縮した。残)青をシリカゲルカラム(1:3、
メタノール;塩化メチレン)で分ト■精製し、酢酸エヂ
ルーエタノールから再結晶して、1コ1色の目的物(月
水和物> 230 malを得た。 融点″ 220〜222℃ 元素分析: C24H2<F2 N÷03 ・月1−1
20IIl粋埴 C: 62.Go 、I」: 5.4
0 、N : 12.17実測1直 C: 62.60
 、 l−1+ 5.10 、 N : 12.07実
施例]6 1−シクロプロピル−b、u−シフルア1[1−’1 
、4−ジヒドロ−4−オキソ−7−(1−ピペラジニル
)−3−キノリンカルボン酸・銀塩の合成 1−シクロプロピル−6,8−ジフルオロ−1,4−ジ
ヒドロ−4−ンj−4.ソー7−(1−ピペラジニル)
 −3−キノリンカルボンR,20011tlを水酸化
す1〜リウム25 m5Jを含む水溶液(10m)に溶
かし、硝酸銀100 mg水溶液(5#liりを加える
とただちに結晶が析出した。反応液を5℃で一夜放置後
、析出物を濾取して淡褐色の目的物(ど水和物)220
mgを17k。 融点 180〜183℃(分解) 元素弁’rli: C+r I−1+s F2 N30
3 AQ ・HH20δ1紳11IiC:42.2B 
、 H: 3.96 、 N : 8,70実測11ダ
XC:42,3& 、 l−1: 3,66 、 N 
: 8,69実IJ[Ii例17 1−シフロブし]ピル−6,8〜ジフルオ[二+−1.
4−ジヒドロ−1−(4−メチル−1−9ピペラジニル
)−4−オキソキノリン−3−カルボン酸・銀塩の合成
1−シクロプロピル−6,8−ジフルオロ−1,4−ジ
ヒドロ−7−(4−メチル1−−ピペラジニル)−4−
オキソキノリン−3−カルボン酸を用い′(、実/)I
f4t!1l116と同様な方法で融点186へ、 1
89”C(分67)の目的物を19だ。 実施例18 1−シフロブ[1ピル−6,8−ジフルオロ−1,4−
ジヒドロ−7−(4−メチル−1−ピペラジニル)−4
−オキソ−3−キノリンカルボン酸の合成1−シクロプ
ロピル−6,8−ジ−フルオロ−1,4−ジヒドロ−4
−オキソ−7−(+−ピペラジニル)−3−キノリンカ
ルボン酸・j= Ifffi塩13 、54 Siおよ
び無水酢酸ナトリウム5.76 (Jを8796ギ酸8
0 rrβに加えてとかし、100〜120℃で2詩間
攪拌した。 反応液を濃縮後、残渣に水50−を加えてとかし、再び
濃縮乾固し乾燥した。ついで得られた残渣を水にとかし
て70dまで濃縮し、5℃で一夜放置後、析出晶を濾取
し氷水、エタノールおよびエーテルで順次洗浄して十分
に乾燥し1〔。この結晶を1規定水酸化す1〜リウム水
溶液70dに加熱溶解し、熱時酢酸で吐7〜8に調整し
て放冷後、析出物を濾取しエタノールおよびエーテルで
順次洗浄し、100℃′r−5時間減圧乾燥して無色i
t U:品の目的物11.79 gを得た。 融点221〜222℃ 元素分析: C+a 1119 FZ N303a目N
IQ CJ ’、59.50 、 H: 5.27 、
 N = 11.56実測fi C:59.C)4 、
 H: 5,19 、 ’;’J : 11.63試験
例1 抗菌スペクトル 抗菌品1℃験tよ日本化学療法学会指定の方法に卑じて
実施された。その結果を表1に示す。 まlこ1lia床分離の1lili炎球t’i16株に
対する感受性を表2に示づ。 表2 肺炎球菌(臨床分離株)に対する感受性試験例2 マウス全身感染症に対する効果 1群5匹のIORマウスを用い、腹腔内に大腸菌(E、
coli 〜IL 4707)を4,9X 106個/
マウス、緑膿菌(p 、aeruginosa l l
 [) 1210)を3.5×105個/マウスまたは
黄色ブドウ球菌(S 、aureus 3 ll1it
h)を7Xi05個マウス注入し、その1時間後に薬物
を7用硝(黄色ブドウ球菌の場合は5用l)夫々−回経
口投与し、薬物用mと生存率のカーブから50%の動物
が死を免れ治癒する用ffi’(EDso)をめた。 表3にその結果を示す。 木光明の実施例8化合物、実施例11化合物実施例15
化合物は、対照としC用いたシプロフロキシ台ナンに対
し、非1郭に優れた感染防禦効果を示した。 0) ) 手続ネi’$7正−輸発) 昭和60年3月8日 1、事件の表示 昭和58年 特許願 第232560号2、発明の名称 キノロンカルボン酸誘導体 3、補正をする者 事件との関係 特許出願人 住 所 東京都千代田区神田駿河台2丁目5番地名 称
 (139)杏林製薬株式会社 4、代理人 住 所 東京都千代田区神田北乗物町16番地〒101
 英 ビル3階 補正の内容 1.明細書簡11頁1行目の末尾に続いて次の文を加入
する。 [またYが塩素である化合物、3−クロロ−2,4,5
〜トリフルオロニトロベンゼンは例えば3−クロロ−4
−フルオロアニリンより数工程で製造することができる
。」 26同第10頁11行目以下の化学反応式を下記3、同
第11頁1行目と2行目の化学反応式を下記の如く訂正
。 「 4、明細書第24頁下から3行目において、「とかし、
」と「100〜120℃」の間に次の文を加入する。 [37%ホルマリン6.0a+!を加えて」5、明細書
箱25頁12行目と13行目の間に次の文(実施例19
〜24)を加入する。 [実施例19.8−クロル−1−シクロプロピル−6,
7−ジフルオロ−1,4−ジヒドロ−4−オキソ−3−
キノリンカルボン酸エチルの合成 公知化合物3−クロル−4−フルオロアニリン100g
に無水酢酸200dをゆっくりと加え、そのまま30分
間放置した。反応液を氷水1J2中に注いで析出物を濾
取し、水−エタノールから再結晶して融点118−11
9℃のN−(3−クロル−4−フルオロフェニル)アセ
タミド119.8gを得た。 III硫酸540dにN−(3−クロ/1z−4−フル
オロフェニル)アセタミド180yを加えて塩−氷浴中
で攪拌しながら、濃硝酸(SEl、G r、1.42)
 500 #ll!を5−10℃1時間で滴下した。同
温で2時間攪拌後、反応液を氷水中に注いで析出物を濾
取し、アセトニトリルから再結して融点114−115
℃のN−(3−クロル−4−フルオロ−6−ニトロフェ
ニル)アセタミド190gを得た。 濃IJ!lll300#Ii!及びエタノール1(の混
合溶液中にN−(3−クロル−4−フルオロ−6−ニト
ロフェニル)アセタミド188gを加えて2.5時間還
流した。冷接、反応液に氷水2(を加えて析出晶を濾取
、水洗、風乾して融点135〜145℃の3−クロル−
4=フルオロ−6−ニトロアニリン149gを得た。 酢酸1.5(に3−クロル−4−フルオロ−6−ニトロ
アニリン147gを加えてとかし、攪拌しながら、塩素
ガスを18−20℃で2時間吹込んだ。反応液を氷水2
(中に庄いて析出晶を濾取、水洗し、エタノールから再
結晶して融点155〜156℃の2.3−ジクロルー4
−フルオロ−6−ニトロアニリン146gを得た。 無水アセトニトリル800dに無水塩化第二銅108.
.5g及び亜硝酸【−ブチル99,6gを加えて攪拌し
ながら、2.3−ジクロル−4−フルオロ−6−ニトロ
アニリン145gを60〜62℃で少量ずつ30分間で
添加した。 反応液を60〜65℃で30分間撹拌後、濃塩酸700
−及び氷水1.4.eの混合溶液中に注いでベンゼンで
抽出し、有機層を希塩酸及び水で順次洗って無水芒硝で
乾燥し、濃縮残漬を蒸留により精製して沸点136〜1
43℃/ 25 mm HQの2.3.4−トリクロル
−5−フルオロニトロベンゼン125.9gを得た。 フッ化カリウム64.9gを含む無水ジメチルスルホキ
シド(DMSO)2301+112懸濁液に2.3.4
−トリクロル−5−フルオロニトロベンゼン54.4S
Fを140℃で加え、同温で10分間攪拌した。反応液
を氷水700d中に注ぎ、石油エーテルで抽出して有機
層を水、炭酸カリウム水溶液及び水で順次洗い、無水芒
硝で乾燥後、濃縮して得られる残漬を蒸留により精製し
て沸点95〜108℃/30MHgの3−クロル−2,
4,5−トリフルオロニトロベンゼン9.7gを得た。 シクロプロピルアミン2.8g及び1〜リエチルアミン
5.1gを無水トルエン20dにとかし、3−クロル−
2,4,5−トリフルオロニトロベンゼン9.7gを含
む無水トルエン30mの撹拌溶液に3〜5℃40分間で
滴下した。同温で3時間撹拌後、反応液を氷水15.0
−中に注いで塩化メチレンで抽出し、有機層を水洗、無
水芒硝で乾燥して濃縮した。 得られた残漬をシリカゲルカラム(溶媒: n−ヘキサ
ン−塩化メチレン)により精製して橙赤色油状の3−ク
ロル−2−シクロプロピル−4,5−ジフルオロニトロ
ベンゼン4.49を得た。 3−クロル−2−シクロプロピル−4,5−ジフルオロ
ニトロベンゼン4.4gに無水酢酸15−に加えて室温
で30分間攪拌した。 反応液を氷水10OIRIl中に注ぎ、炭酸カリウム末
を加えて過剰の無水酢酸を分解して5℃で12時間放置
後、析出物を濾取し酢酸エチル−〇−ヘキサンから再結
晶して融点98〜99.5℃のN−(2−クロル−3,
4−ジフルオロ−6−ニトロフェニル)−N−シクロプ
ロピルアセタミド2.7gを得た。 N−(2−クロル−3,4−ジフルオロ−6−二1−口
フェニル)−N−シクロプロヒルアセタミド2.7gを
エタノール50−にとかし、10%パラジウム炭素0.
5gを加えて常圧水素気流中2〜3℃で40分間撹拌し
た。 反応液を濾過して濃縮後、結晶性残漬を室温で10時間
真空乾燥した。これを無水ジメチルボルムアミド(DM
F) 1511+1!にとかし、亜硝酸【−ブチル1,
72 gの無水DMF10d溶液に50〜52℃13分
間で滴下した。 反応液を同温で5分間撹拌後、氷水中に注いでエーテル
で抽出し、有機層を水、希塩酸及び水で順次洗って無水
芒硝で乾燥し、濃縮して得られる残漬をシリカゲルカラ
ム(溶媒:n−ヘキサン−酢酸エチル)により精製し、
石油エーテルから再結晶して融点60.5〜61.5℃
のN−(2−クロル−3,4−ジフルオロフェニル)−
N−シクロプロピルアセタミド0.44 !?を得た。 20%希塩酸7dにN−(2−クロル−3,4−ジフル
オロフェニル)−N−シクロプロピルアセタミド0.4
4 gを加え、80〜100℃で6時間撹拌した。反応
液を氷水中に注ぎ、水酸化ナトリウム水溶液で弱アル)
Jり性としてエーテルで抽出し、有機層を水洗、無水芒
硝で乾燥した。濃縮後、得られる残渣を分取用シリカゲ
ル薄層クロマトグラフィー(溶媒:石油エーテル−エー
テル)により単離精製して橙色油状のN−シクロプロピ
ル−2−クロル−3,4−ジフルオロアニリン100 
my を 得 Iこ 。 N−シクロプロピル−2−クロル−3,4−ジフルオロ
アニリン100IIIyにエトキシメチレンマロン酸ジ
エチル110ORを加え、生成するエタノールを除去す
る為窒素ガスを吹き込みながら10.5時間、100〜
135℃の油浴上で撹拌した。冷接、これにポリリン酸
1gを加えて125〜135℃の油浴上で3時間撹拌後
、反応液を氷水中に注いでクロロホルムで抽出した。有
機層を炭酸カリウム水溶液及び水で順次洗い、無水芒硝
で乾燥して濃縮し、得られた残渣を分取用シリカゲル薄
層クロマトグラフィー(溶媒:エーテル)により単離精
製して無色針状晶の8−クロル−1−シクロプロピル−
6,7−ジフルオロ−1,4−ジヒドロ−4−オキソ−
3−キノリンカルボン酸エチル11#lyを得た。融点
160〜162.5℃ 実施例20.1−シクロプロピル−8−クロルー6−フ
ルオロ−1,4−ジヒドロ−4−オキソ−7−(1−ピ
ペラジニル)−3−キノリンカルボン酸の合成 1−シクロプロピル−8−クロル−6,7−ジフルオO
−1,4−ジヒドロ−4−オキソ−3−キノリンカルボ
ン酸エチル11a+y及び無水ピペラジン15#yをD
MSOO,5mに加えて50℃で4@間撹拌した。反応
液にクロロホルムを加えて水洗し、無水芒硝で乾燥して
濃縮後、得られた残渣から分取用シリカゲル薄層クロマ
トグラフィー(溶媒ニトリエチルアミン−アセトニトリ
ル−クロロホルム)により主生成物を単離した。これを
1規定水酸化ナトリウム水溶液0.15 dに加え、7
5〜80℃の水溶上で45分間加熱した。冷接、反応液
を濾過し、濾液を酢酸で中和してから約0.1−まで濃
縮し、放置して析出する結晶を濾取し、冷水及びエーテ
ルで順次洗い乾燥して融点234〜236.5℃(分解
)の目的物1.51Rgを得た。 質量分析(ra/e ) :367 (M+2” )、
365 (M+ )、 323(100%)、 279、238 実施例21.8−クロル−1−シクロプロピル−6−フ
ルオロ−1,4−ジヒドロ−4−オキソ−7−(1−ご
ベラジニル)−3−キノリンカルボン酸エチルの合成無
水ピペラジン0.39 gのDMSO溶液に8−クロル
−1−シクロプロピル−6,7−ジフルオロ−1,4−
ジヒドo−4−オキソー3−キノリンカルボン酸エチル
0.309を加えて50〜60℃で75分間撹拌した。 冷接、反応液にクロロホルム10d及び炭酸カリウム水
溶液を加えて振どう後、クロロホルム層を分取し、水層
をさらにクロロボルム5−で3回抽出した。クロロボル
ム層を合し、そこから3%希塩酸5IIl!で3回抽出
し、次いで希塩酸層にクロロホルム15−を加え、水酸
化ナトリウム水溶液にてIIHIO〜11としてすばや
く分液し、クロロホルム層を水洗し無水芒硝で乾燥接、
残渣にアセトン10I11を加えて析出品を濾取し、無
色針状晶の目的物0.089を得た。融点184〜18
6℃実施例22.8−クロル−1−シクロプロごルー6
−フルオロ−1,4−ジヒドロ−4−オキソ−7−(1
−ピペラジニル)−3−キノリンカルボン酸及びその塩
酸塩の合成 8−クロル−1−シクロプロピル−6−フルオロ−1,
4−ジヒドロ−4−オキソ−7−(1−ピペラジニル)
−3−キノリンカルボン酸エチル70■を1規定水酸化
ナトリウム水溶液1.5dに加え、80〜85℃の油浴
上で30分間撹拌した。熱時反応液に活性炭を加えて濾
過し、濾液を酢酸で中和してから一夜5℃で放置後、析
出晶を濾取して無色プリズム品の目的物42a!Jを得
た。融点244.5〜246.5℃(分解) また、上記母液にra1!l酸5滴を加えて析出晶を濾
取し、冷水及びエーテルで洗浄し゛C無色プリズム晶の
塩i!!塩13IyIを得た。 融点260℃(分解) 元素分析: Car Her C1FNa Oa ・H
zO計算値 C: 53,20 )−1: 4.99 
N : 10.95実測値 C: 53,291−1 
: 4,70 N : 10.88元素分析: Car
 Her Cj! FN303 ・1−1c、e計算値
 C: 50.76 H: 4.51 N : 10,
45実測値 C: 50.66 H: 4.55 N 
: 10.37実施例23.8−クロル−1−シクロプ
ロピル−6−フルオロ−1,4−ジヒドロ−7−<4−
メチル−1−ピペラジニル)−4−オキソ−3−キノリ
ンカルボン酸エチルの合成 8−クロル−1−シクロプロピル−6,7−ジフルオ0
−1.4−ジヒドロ−4−オキソ−3−キノリンカルボ
ン酸エチル0.30 (JとN−メチルビペラジン0.
199とを実施例21と同様に反応、後処理し、酢酸エ
チルから再結晶して淡褐色針状晶の目的物0.129を
得た。融点197〜198℃ 実施例24.8−りOルー1−シクロプロピル−6−フ
ルオロ−1,4−ジヒドロ−7−(4−メチル−1−ピ
ペラジニル)−4−オキソ−3−キノリンカルボン酸及
びその塩酸塩の合成 8−クロル−1−シクロプロピル−6−フルオロ−1,
4−ジヒドロ−7−(4−メチル−1−ピペラジニル)
−4−オキソ−3−キノリンカルボン酸エチル110m
gを実施例22と同様に反応、後処理して淡褐色針状晶
の目的物2■を得た。融点300℃以上、質量分析(m
/e ):381 (M+2>、379 (M+ 、1
00%)、335.299゜また、無色針状晶のその塩
酸塩79■を得た。融点218℃(分解) 元素分析+ (、I8HogC,eFN303・HCj
!・415Hz O 計算値 C: 50.20 H: 5.05 N : 
9.76実測値 C: 50.13 H: 4.75 
N : 9.796、明I書第26〜27頁の表1を下
記の如く訂正する。
[Yo chlorine,
Fluorine is also characterized in that it acts on a compound represented by a methylating agent and, if necessary, hydrolyzes the ester. (In the formula, R(, ester, Y represents a salt point, fluorine j; or methyl 1) Compounds represented by the formula 1), hydrates thereof, and methods for producing salts thereof. 3. Detailed description of the invention Invention 1 has the general formula (wherein R is Hydrogen, methyl, 1]-21-benzyl J
, f: L l aminopencil, Y is manuscript, fluorine (y) represents methyl '!l'>'c represents a novel -
This invention relates to noroncarboxylic acid derivatives, their salts, their production methods, and their uses as antibacterial agents. The compound of the present invention was newly synthesized by the present inventors,
Kino0nnoj Lebon MJ, sushi test shooting by prior art
Its antibacterial activity is widespread, including Dollar X Yangt/L and Yin 11 bacteria, and it exhibits 11 (Chuan 54-c 9) J Song, with good absorption in animals. It was discovered that the characteristics were different, leading to the present invention. Next, a method for forming a horn of the compound of the present invention will be explained. (In the formula, X represents halogen, R'+, r7i', 3- or lower alkyl, R represents hydrogen, methyl, 11-21-benzyl, or 1)-aminobenzyl, and Y is as defined above. (same) Of course, the compound i''i represented by the formula [IF] is J
(By avoiding the reaction of the compound represented by [I[1], the compound of the present invention represented by the formula [I]-c- is synthesized. However, a compound of the formula [nl] where R is p-21-[1hensyl) In the case of 1=, the compound [1 group] shown in Table 4' can be converted to an amino group by the formula [I In this case, the compound of the present invention can be obtained by hydrolyzing the reaction product with the compound represented by formula [1[1] according to a conventional method and converting one sprue into carbonic acid. Compounds of formula CI) where rR is p-aminobenzyl are compounds of formula (I) where R is hydrogen or its Nisder (IV) (wherein RI represents hydrogen, methyl, p-nitrobenzyl or II-aminobenzyl). ) and p-21-benzyl halide, a compound of formula (I) in which R is 11-21 helobenzyl or its nis-glue, the nitro group is reduced to an amino group as above, and the essential Then, hydrolyze the ester? It can also be synthesized by In addition, the compound of formula [1] in which R is methyl can be obtained by adding a methylating agent to the compound of formula (IV). , it can also be synthesized by hydrolyzing an ester. The reaction between the compound represented by the formula [I[] and the compound represented by
It is carried out in the presence of polar solvents such as F>, dimeryl sulfate (D, MSO), hexamethylphosporizamide, pyridine, viroline. Reaction frequency is from room temperature
200°C, preferably selected within the range of 60 to 160°C.More precisely, the compound represented by the formula "II" and the compound of the formula [I[1] In 2 to 1018 volumes of the above solvent, 60 to 1
20"C for 1 to several hours. Further, the reduction of a compound in which R is p-nitrobenzyl to a compound in which R is 1)-aminopencyl is carried out under a catalyst such as palladium charcoal or platinum. , contact with 32 elements in a hydrogen stream or metals such as iron, tin, zinc, or metals!
; It can be carried out by a commonly known method such as metallurgy using insects. In addition, the reaction between the compound of formula 1 [1v] and p-21~(]benzyl halide, such as chloride, blow, and p-21-, can be carried out using IBH1!, such as triedyl j', in a suitable solvent.
The reaction can be carried out at a temperature ranging from room temperature to the boiling point of the solvent used (8) in the presence of minerals, potassium carbonate, etc. Furthermore, Iζ, methylation of compounds of formula (IV) (e.g. -3-methyl, central methyl, dimel l1jt n'j
Alternatively, use a commonly used methylating agent such as formalin or a methylating agent.
If desired, the compound represented by the formula [di] in 11 can be converted into its salt according to the method. t+bt acid, phosphoric acid, etc.
Salt of organic acid, methanesulfonic acid, lactic acid, right 1 of Nishi 1 acid tank
Which acid 122 or carbon II? Sodium J-Chang, Potassium salt, Magnesium salt, Calcium JO,
Examples include aluminum laminate, cerium salt, chromium 1+Δ, :pal 1 salt, copper salt, iron salt, zinc salt, silver 1λ crystal, and nickel B. The compound represented by the general formula [■], which is the starting material of the present invention, is also a new compound, and can be synthesized, for example, by the following formula 1-. 2 becomes the starting compound
, 3,4,5-tetranor A lobenzene is known, and can be produced, for example, by converting 1.2,3°4-deraful A lobenzene into 21,1'. Monkey (T
eLllallOLIl'oll, 23.4719
゜196 phi 1-). [ Compound Jj of the present invention represented by general formula [I], its hydrate, and its salt exhibit excellent antibacterial properties against Gram-negative bacteria and Durham-positive bacteria. V. When used as a mulberry product, good absorption is desired. For this reason, the absorbability has been increased by introducing a ``1 group'' into the 8th position. Depending on the route, conventional pharmaceutically well-known forms, tablets,
Applicable to capsules, powders, soft drinks, injections, 111N dots, herbal medicines, etc. Next, the V-soaking method for the compound of the present invention and its anti-F:i properties will be explained in detail with examples. Example 1 2-Schiff[1propylamino-++,4+5'
Synthesis of 2,3,4,5-atrafluΔ[21-toD/
\Toluene 5#Ii of 2 mβ of cyclopropylamine in 20 ml of 1-toluene of 3.1 J of '61! 1 solution
The mixture was added at a temperature below 0°C and stirred for 1 hour. The 4Ia layer was separated without adding Bengin 507 and ice water 20#112 to the reaction solution, and after washing, drying anhydrous sodium sulfate, and concentrating under reduced pressure, the residue was purified using a Noratsushico column to obtain the desired product 2, ', +
5gj3J:bi11-cyclopropylamino-21J
+ J-l-Riful A Loji 1-L1 Henjin was isolated. Example 2 2-(N-cyclop1]biru)aledamide 3°4.
5-1 - Synthesis of cyclopropylamino compound of lifluoronitrobenzene (Example 1) 0.9!1 10 Il of acetic anhydride
When two drops of sulfuric acid are added to the solution, heat is generated and the orange color of the solution instantly disappears. After 5 minutes, the reaction solution is poured into ice-potassium carbonate aqueous solution and extracted with ether. The 1-chill layer was washed with dilute IAf 6M and water, and the solvent was distilled off after drying.
08 Obtain q. Light color prism product, melting point 91-92"C. Elemental analysis: Cu t-1s l"3 N203iil
Gentleman (lrl C: 48, 19, 1": 3, 31. N
: 10,21 fruit, (111111C: 48.53
, l-1: 3. .. 30. N: 10.31 Example; 3 2-(N-Schiff "Jp[" building)aledamide-3°4
,! ii ~ Synthesis of acetyl form of Riful A loaniline (Example 2>o, ag is 1-tanol 407 j3J-'O
' ) It The total volume of iIL of 20 mQ of acid was solved and 10% P d '(',, 200 my was added and hydrogenation was carried out at normal pressure for 50 minutes). After filtering the reaction solution, reduce the volume by 1 clot and remove the residue.++ n Form 1001II
L FB'AY LjJ charcoal saw 'J water fJ liquid, water ('M+'i Next wash 1,111-dry with sulfur salt and distill off the solvent, i'=? l)] 11 to L Crystallized from tanol C purpose 1 0, ', 1',) 4 X7
tl. Pale brown brism crystals, melting point 171 to 173
℃1° elemental analysis: C1l t-In F3 N2O3 calculation C: 54,10; l・l: 4.54. N
: 14.47 Actual value C: 54.26, H:
4.57. N: 11. :i. Example 4 N-(2,3,4-triful A-R), -N
-Synthesis of cyclopropylacetamide 72921 units (Example 3)
10 mQ of reformamide (DMF), 0.9 mq of amyl nitrite distilled into a nail i, anhydrous DMF 5
Dropped into the mQ solution at 60-65°C for 20 minutes. Add cold water, add 150 tres of water, wash sequentially with water, dilute hydrochloric acid and water for a few days. Ichinoratsushi column of blue (
2: J+'l-"\Kirin: lit acid 1 del)" was reacted with 1h to obtain the target 4'I+0.95gG. n-
When recrystallized from Hekilin, colorless iI-like fi': i product,
The melting point is 99-100°C. Elemental analysis: Co Ll+or: Nz 0IiI calculated value C: 57. GA, N: 4.40. N:
6.11 Actual measurement 1aC: 57.85, l-l:
4.32. i'J: (i, N Example 5 N-Schiff 1 Koshi UJ Building-2, 3, 41-Reflua D
Synthesis of aniline 1 - Amide rest (Example 4) 950I++y 1
0% caustic sorter solution 30mQ I+) J:bi]-tanol 101nQ 1+V + 80...90°C
So 411. ! Stirred for 7 hours. Extracted with cold kneading, washed with water, dried with anhydrous sodium sulfate and condensed, resulting in a pale oily target product of 0.6
39 ('7k. Example 6 DiLdel N,-Schiff1]p[2]pil-N-<2,3
゜4-triflu A lov'-nyl) aminomethylene mash]
Synthesis to Ne 1 71 Niline body (Example 5) Mix 0.69 g and 1-toxymethylene ζ [ln diethyl + and 4 g to 1! +O□"160'C(1,,'+ II: f l
! D Its J'F Shita. After 50 years of cold, Fludge-1
A column (11-hexane-ethyl acetate) produced the target product as a colorless oil (lJ6≦1, 111k. Synthesis of -1'l-1,4-dihydre 11-4-/1xoquinoline-3-carboxylene 1 - Maloney 1 integrated (Example 6) 554In! j to 4U of polyphosphoric acid, 12(i=130”C-(111
) was stirred for IX2. Cold welding, add ice water, extract chloroborum, dry mirabilite, evaporate, and purify the residue in a flash column (1:3, ethyl acetate: methylene chloride). Recrystallized from 1.2l-lyl to obtain 2j1 (color 11-like object 236rn
:I celebrated l. Melting point 175-'17G" Q element 4; min (1
1: Cus 1112 F3 NO3 Crying Hani C:
57.88. H: 3.89. N: 4,50 Actual value C: 57.68. El: 3.74. N
: 4.50 Example 8 1-cyclopropyl-0,8-diflu>1o-1,4-
Shijidraw 7-(4-methyl-1-bibe0noshell)-
Synthesis of carboxylate compound of 4-oxoquinoline-3-carvone nI2 (Example 7) 200 mg and 200 mg of N-methylpiperazine were added to dimethyl sulfoxide (DMS).
O)! In addition to sn & 90~100°Cc2 +1? Stir for a while. ) R cotton cylinder, residual pickle paste [IL1 Borm GOtrd
! Dissolve the chloroform layer in an aqueous potassium carbonate solution, wash with water, and dry anhydrous sodium sulfate. Moon: Wakimizu III -IZ-c111F+ tril
I hit II. Id (remove H, a, iH, -R/I etc. - (1' l-17t Δ correction C) barring. Remaining: ?j 'a'It'% Granoy (OI) 5-C1ε, 5.4% Ann Inia water:
Methanol 5: () 5 - □ 30 Nia 0) fractionated, and further silica gel tunorum (black) form ['l 1 1 1 form: methanol: 30 N 7 2) 7 water - 10 :10:3), and recrystallized from methanol to give colorless needle crystals.
g) -ノ. ), melting point 220-221''C0 element i)・
9 minutes iji: Cu81 (+9F2 N30361
ξn11 C: 59.50. II: 5.27
.. N: 11.56 actual measurement vessel C: 59.24.
II: 5.21. N: +4,47 fruit/#Example 9 1-Schiff IJ '71-1 Building-6,8-Sea True A
Synthesis of -Ul-7-(L-Viverasyl)-11-4xoni-1-noline-3-carboxylic acid Calxylene-1-141 (Real/11!!Example 7) 3
0nrg t3 J: Processing of Uvivesicin 4Q mg into L) MSOlmff Stirred at 90-100°C for 1 hour. Thereafter, it was treated in the same manner as in Example 8 (]; and recrystallized from methanol to obtain a button-shaped object (3 mg).
It's 17. Melting point: 270°C ~ (decomposition). Principal amount (1j: CIF 11+r Fz N20B
911'n 11fJ C: 58,45. l-l
: 4.91. N: 12.03 Actual law I'i
C: 58.37. l-1: 4,80. N:
+2.20 Example 10 1-SikuI'lp['biru-6,8-diflu JII-
1,/1-dihydro-7-(1-piperazinyl)-4-
71 Synthesis of xo-1-purine-3-carboxylic acid piperazine i, +37 sulfo-4-silyl 1-15
mf! 8f of carboxylate in solution (Example 7) 0.8
29 was added and stirred at 60'C for 2 hours. After cold welding, 200 liters of chlorovolum was added to the reaction solution, washed with an aqueous potassium carbonate solution, extracted with 1% hydrochloric acid, and the extract was diluted with PI-110-44 with an aqueous sodium hydroxide solution and quickly extracted with chloroform. . Wash a little bit of J-hol 11 with water, anhydrous sodium sulfate (after drying, concentrate until crystals begin to precipitate, add hot acetate, cool, collect the precipitated product by filtration, and obtain a colorless 11-like product) 0.87 g to 111 points...J point
211-212℃ element Xj>41'+: Cf9 1-
121 F2 N3 03:1 Arithmetic 11&C:Go, 4
7, H: 5. G1, N: 11.13 Actual value C: 60.50, H: 5.50, N
: IL14 Example 11 Synthesis of 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid ethyl compound (Example 10) 0.87i7 to 1N
In addition to 20mQ of sodium hydroxide aqueous solution, 100°G"
CI poetry was stirred. Cold welding, the reaction solution was neutralized with acetic acid C and Jl
i Filter the output and re-dilute from methanol to 11,+4 Ll.
(Jp, l, (Qa1.J,7” A!% O[
1% 4% hydrate, 0.60 tons I+:j+'71. Melting point 270-270.5'C (decomposition) Original component 41i:
C+r I-1+r F2 N303 ・MHz 0r
it U) lfj C:57.71, I-1:
4.99. N: 11.88 actual measurement fla C: 57.8
5, H: 4.92, N: N, 88 Example 12 1-Schiff [propyl-6,8-difluoro-1,4-
Synthesis of dihydro n -4-:4:lso~7-(1-vinyl\resinyl), -3-gynolinecarboxylic acid 1zl salt 1-cyclopropyl-6,8-diflu4 a- 1, 4
-dihydro-4-'Axo7~(1-piperazinyl)
=3-quinolinecarboxylic acid 1.09'd* J2. i
Wj 20m! After refrigeration and concentration, the residue was recrystallized from methanol (1: i, io.
I got g. Melting point: 300°C (min.) Y) Elemental content: A/F
: C++ +-117F2 N! Os ・l-I
Cf value C: 52°93, l-f: 4.
TO, N: 10.89 Actual value C: 52,97
, H: 4. GG, N: 10,90 Example 1
3 1-Shiflov 1] pill-6,8-dinol/1゛ro 1.
4-dihydro-7-(4-methyl-1-piperazinyl)
-4-'; Synthesis of A-1-so-3-quinolinecarboxylic acid/l-fukuic acid 1-sifurob [I-bil-G, 8-cyfuro-1' [1-
1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-4-norinnoJrubonp H
7m and q were treated in the same manner as in Example 12, and sequentially recrystallized from water and methanol to form a fluorine. ! (Color 11 object of the item (
monohydrate) 12318 g (q. Melting point 266℃ (
B2 solution) Elemental analysis: Cm l-1+a Fz N30
B ・l-lCf ・l-120 total "C?1ifi C
:51.74, l-1:5. '30, N: 10
.. 0G actual measurement 1ifi C: 52.03, ti:
5.20, N: 10.20 Example 14 1-Siflov[1vir-6,8-difluoro-1,4-
Dijito D-7” (4-(Il-21-lobenzyl)
Synthesis of -1-piperazinyl)-4,-oxo-3-=1-nolinecarboxylic acid 1-sifurob[-1vir-6,8-cifurob 1[]-]
1.4-Dihydro1]-4-oxy-7(1-piperazinyl)-3-21-nolino J Rubon 5p, 900 N
3 was dissolved in 20 m dimethylformamide ([)lvlF) and j)-nitrobenzyl 7 II ? 84
0.4 d of 1-lyethyleneamine was added to 0 m9 Jj, and the mixture was stirred at 80 to 90°C for 10 hours. Reaction: I
After concentrating 1, water was added to the residue and the precipitate was collected by filtration, D)
Recrystallize from N4F-ethanol to obtain 845 myl of brown crystal target product (Z water [1 substance) (9%). Melting point: 195, 197°C Elemental analysis: C24N22 F2 N40: ・j41
40 calculation direct C: 58.77, H: 4.6G
, N: IL42 real 1ltNij7 C:58,83
, l-1: 4.48, N: N, 35 Example 15 714-(1)-aminobenzyl)-1-piperazinyl) to 1-1-cyfrobropyru-6-diflu, 40-1.
4-dihydro-4-oxo-3-quinolinecarvone R)
Synthesis of 1-cyclopropyl-6,8-dinormelo-1,4-dihydro-7-(4-(++-+--lobenzyl)-1-
800m! 7 in 20 mQ of glacial acetic acid
lf”?shi, 10?6 lid/ CI SOIII
gt IJII knee' (very wet IQ li' L <
'; Gara water string gas 200mf! /! , absorbed. After filtration of the reaction solution 4, ice water was added to the filtrate, neutralized with sodium hydroxide (aqueous solution), extracted with chloroform, dried over anhydrous sodium sulfate C, and concentrated. Residual) Blue was transferred to a silica gel column (1:3,
It was purified by fractionation with methanol (methylene chloride) and recrystallized from edyl acetate-ethanol to obtain the desired product (moon hydrate > 230 mal). Melting point: 220-222°C Elemental analysis: C24H2<F2 N÷03 ・Month 1-1
20IIl Suishoku C: 62. Go, I”: 5.4
0, N: 12.17 Actual 1st shift C: 62.60
, l-1+ 5.10, N: 12.07 Example] 6 1-cyclopropyl-b, u-cyflua 1[1-'1
, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid silver salt synthesis 1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-one j-4 .. So7-(1-piperazinyl)
-3-Quinolinecarvone R, 20011 tl was dissolved in an aqueous solution (10 m) containing 25 m5J of hydrogen hydroxide, and 100 mg of silver nitrate aqueous solution (5 #1) was added, and crystals precipitated immediately. The reaction solution was heated at 5°C. After standing overnight, the precipitate was collected by filtration and the light brown target substance (hydrate) was 220
mg to 17k. Melting point 180-183℃ (decomposition) Elemental valve'rli: C+r I-1+s F2 N30
3 AQ ・HH20δ1Gen11IiC:42.2B
, H: 3.96, N: 8,70 Actual measurement 11 da XC: 42,3&, l-1: 3,66, N
: 8,69 Real IJ [Ii Example 17 1-Siflovized] Pill-6,8~Difluoro[2+-1.
Synthesis of 4-dihydro-1-(4-methyl-1-9piperazinyl)-4-oxoquinoline-3-carboxylic acid silver salt 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7- (4-methyl1-piperazinyl)-4-
Using oxoquinoline-3-carboxylic acid'(, real/)I
f4t! Melting point 186 in the same manner as 1l116, 1
The target product of 89"C (min 67) is 19. Example 18 1-Siflov[1Pyr-6,8-difluoro-1,4-
Dihydro-7-(4-methyl-1-piperazinyl)-4
-Synthesis of oxo-3-quinolinecarboxylic acid 1-cyclopropyl-6,8-di-fluoro-1,4-dihydro-4
-oxo-7-(+-piperazinyl)-3-quinolinecarboxylic acid j = Iffi salt 13,54 Si and anhydrous sodium acetate 5.76 (J = 8796 formic acid 8
The mixture was added to 0 rrβ and stirred at 100 to 120°C for 2 hours. After concentrating the reaction solution, 50% of water was added to the residue to dissolve it, and the mixture was again concentrated to dryness. Then, the obtained residue was dissolved in water and concentrated to 70 d, and after standing at 5°C overnight, the precipitated crystals were collected by filtration, washed successively with ice water, ethanol, and ether, and thoroughly dried. The crystals were heated and dissolved in 70 d of a 1 N hydroxide aqueous solution, adjusted to a concentration of 7 to 8 with acetic acid when hot, and allowed to cool. The precipitate was collected by filtration, washed sequentially with ethanol and ether, and heated to 100 'r - Dry under reduced pressure for 5 hours to make it colorless.
tU: 11.79 g of the desired product was obtained. Melting point 221-222℃ Elemental analysis: C+a 1119 FZ N303a N
IQ CJ', 59.50, H: 5.27,
N = 11.56 actual fi C: 59. C) 4,
H: 5,19, ';'J: 11.63 Test Example 1 Antibacterial Spectrum Antibacterial Product 1°C test was carried out in accordance with the method specified by the Japanese Society of Chemotherapy. The results are shown in Table 1. Table 2 shows the susceptibility of the Maruko 1lia bed isolate to the 1lili Flame Ball t'i16 strain. Table 2 Example 2 of susceptibility test against pneumococci (clinical isolates) Effect on mouse systemic infection Using 5 IOR mice per group, Escherichia coli (E.
coli ~IL 4707) 4.9X 106 pieces/
Mouse, Pseudomonas aeruginosa (p, aeruginosa l l
[) 1210) 3.5 x 105/mouse or Staphylococcus aureus (S, aureus 3 ll1it)
h) was injected into mice, and 1 hour later, the drug was orally administered twice (in the case of Staphylococcus aureus, 5 doses), and from the curve of drug dose and survival rate, 50% of the animals He sought ffi' (EDso) to escape death and heal. Table 3 shows the results. Mokkomei Example 8 Compound, Example 11 Compound Example 15
The compound showed superior infection prevention effects compared to ciprofloxinan, which was used as a control. 0) ) Procedure Nei'$7 - Import) March 8, 1985 1, Display of case 1988 Patent Application No. 232560 2, Title of invention Quinolone carboxylic acid derivative 3, Person making amendment case Relationship with Patent Applicant Address 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo Name (139) Kyorin Pharmaceutical Co., Ltd. 4, Agent Address 16-101 Kanda Kita Jimono-cho, Chiyoda-ku, Tokyo
English Contents of correction for the third floor of the building 1. Add the following sentence following the end of the first line on page 11 of the detailed letter. [Also compounds where Y is chlorine, 3-chloro-2,4,5
~Trifluoronitrobenzene is e.g. 3-chloro-4
- Can be produced from fluoroaniline in several steps. 26 The chemical reaction formula on page 10, line 11 and below has been corrected to 3 below, and the chemical reaction formula on page 11, lines 1 and 2 have been corrected as shown below. ``4. In the third line from the bottom of page 24 of the specification, ``combed,
” and “100-120°C” add the following sentence. [37% formalin 6.0a+! 5, and between lines 12 and 13 on page 25 of the specification box, the following sentence (Example 19
~24). [Example 19.8-chloro-1-cyclopropyl-6,
7-difluoro-1,4-dihydro-4-oxo-3-
Synthesis of ethyl quinolinecarboxylate Known compound 3-chloro-4-fluoroaniline 100g
200 d of acetic anhydride was slowly added to the mixture, and the mixture was left to stand for 30 minutes. The reaction solution was poured into ice water 1J2, the precipitate was collected by filtration, and recrystallized from water-ethanol to give a melting point of 118-11.
119.8 g of N-(3-chloro-4-fluorophenyl)acetamide at 9°C was obtained. 180 y of N-(3-chloro/1z-4-fluorophenyl)acetamide was added to 540 d of III sulfuric acid, and while stirring in a salt-ice bath, concentrated nitric acid (SEl, G r, 1.42) was added.
500 #ll! was added dropwise at 5-10°C for 1 hour. After stirring at the same temperature for 2 hours, the reaction solution was poured into ice water, the precipitate was collected by filtration, and the precipitate was reconstituted from acetonitrile, with a melting point of 114-115.
190 g of N-(3-chloro-4-fluoro-6-nitrophenyl)acetamide was obtained. Dark IJ! lll300#Ii! 188 g of N-(3-chloro-4-fluoro-6-nitrophenyl)acetamide was added to a mixed solution of ethanol 1 and ethanol 1, and the mixture was refluxed for 2.5 hours. The crystals were collected by filtration, washed with water, and air-dried to give 3-chloro-
149 g of 4=fluoro-6-nitroaniline was obtained. 147 g of 3-chloro-4-fluoro-6-nitroaniline was added to 1.5 g of acetic acid and dissolved, and while stirring, chlorine gas was blown in at 18-20°C for 2 hours. The reaction solution was poured into ice water with 2
(The precipitated crystals were collected by filtration, washed with water, and recrystallized from ethanol.
146 g of -fluoro-6-nitroaniline was obtained. 800 d of anhydrous acetonitrile and 108 d of anhydrous cupric chloride.
.. 5 g and 99.6 g of [-butyl nitrite] were added, and while stirring, 145 g of 2,3-dichloro-4-fluoro-6-nitroaniline was added little by little over 30 minutes at 60 to 62°C. After stirring the reaction solution at 60-65°C for 30 minutes, concentrated hydrochloric acid
- and ice water 1.4. The organic layer was washed with dilute hydrochloric acid and water and dried over anhydrous sodium sulfate, and the concentrated residue was purified by distillation to obtain a solution with a boiling point of 136-1.
125.9 g of 2.3.4-trichloro-5-fluoronitrobenzene at 43° C./25 mm HQ was obtained. 2.3.4 in anhydrous dimethyl sulfoxide (DMSO) 2301+112 suspension containing 64.9 g of potassium fluoride.
-Trichloro-5-fluoronitrobenzene 54.4S
F was added at 140°C, and the mixture was stirred at the same temperature for 10 minutes. The reaction solution was poured into 700 d of ice water, extracted with petroleum ether, and the organic layer was sequentially washed with water, an aqueous potassium carbonate solution, and water, dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by distillation to a boiling point of 95. 3-chloro-2 at ~108°C/30MHg,
9.7 g of 4,5-trifluoronitrobenzene was obtained. 2.8 g of cyclopropylamine and 5.1 g of 1-ethylamine were dissolved in 20 d of anhydrous toluene, and 3-chloro-
The mixture was added dropwise to a stirred solution of 30 ml of anhydrous toluene containing 9.7 g of 2,4,5-trifluoronitrobenzene over 40 minutes at 3 to 5°C. After stirring at the same temperature for 3 hours, dilute the reaction solution with ice water at 15.0 g.
The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by a silica gel column (solvent: n-hexane-methylene chloride) to obtain 4.49 g of 3-chloro-2-cyclopropyl-4,5-difluoronitrobenzene as an orange-red oil. 4.4 g of 3-chloro-2-cyclopropyl-4,5-difluoronitrobenzene was added to 15-acetic anhydride and stirred at room temperature for 30 minutes. The reaction solution was poured into 100 IRIl of ice water, potassium carbonate powder was added to decompose excess acetic anhydride, and after standing at 5°C for 12 hours, the precipitate was collected by filtration and recrystallized from ethyl acetate-〇-hexane to give a solution with a melting point of 98. N-(2-chloro-3,
2.7 g of 4-difluoro-6-nitrophenyl)-N-cyclopropylacetamide was obtained. 2.7 g of N-(2-chloro-3,4-difluoro-6-21-phenyl)-N-cycloprohylacetamide was dissolved in 50% ethanol, and 10% palladium on carbon was added.
5 g was added thereto, and the mixture was stirred for 40 minutes at 2 to 3° C. in a hydrogen stream at normal pressure. After the reaction solution was filtered and concentrated, the crystalline residue was vacuum dried at room temperature for 10 hours. This was converted into anhydrous dimethylborumamide (DM
F) 1511+1! Nitrite [-butyl 1,
It was added dropwise to 72 g of anhydrous DMF10d solution at 50-52°C for 13 minutes. After stirring the reaction solution at the same temperature for 5 minutes, it was poured into ice water and extracted with ether. The organic layer was washed with water, diluted hydrochloric acid, and water sequentially, dried over anhydrous sodium sulfate, concentrated, and the resulting residue was passed through a silica gel column ( Solvent: n-hexane-ethyl acetate)
Recrystallized from petroleum ether, melting point 60.5-61.5℃
N-(2-chloro-3,4-difluorophenyl)-
N-cyclopropylacetamide 0.44! ? I got it. 0.4 d of N-(2-chloro-3,4-difluorophenyl)-N-cyclopropylacetamide in 7 d of 20% diluted hydrochloric acid
4 g was added and stirred at 80 to 100°C for 6 hours. Pour the reaction solution into ice water and dilute with aqueous sodium hydroxide solution)
After extraction with ether, the organic layer was washed with water and dried over anhydrous sodium sulfate. After concentration, the resulting residue was isolated and purified by preparative silica gel thin layer chromatography (solvent: petroleum ether-ether) to obtain orange oily N-cyclopropyl-2-chloro-3,4-difluoroaniline 100
I want to get my. Add 110OR of diethyl ethoxymethylenemalonate to 100IIIy of N-cyclopropyl-2-chloro-3,4-difluoroaniline, and heat for 10.5 hours while blowing nitrogen gas to remove the generated ethanol.
Stir on a 135°C oil bath. After cold welding, 1 g of polyphosphoric acid was added thereto, and the mixture was stirred for 3 hours on an oil bath at 125 to 135° C., and then the reaction solution was poured into ice water and extracted with chloroform. The organic layer was washed successively with an aqueous potassium carbonate solution and water, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was isolated and purified by preparative silica gel thin layer chromatography (solvent: ether) to obtain colorless needle crystals. 8-chloro-1-cyclopropyl-
6,7-difluoro-1,4-dihydro-4-oxo-
Ethyl 3-quinolinecarboxylate 11#ly was obtained. Melting point 160-162.5°C Example 20. Synthesis of 1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1- cyclopropyl-8-chloro-6,7-difluoro
-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl 11a+y and anhydrous piperazine 15#y
The mixture was added to 5 m of MSOO and stirred at 50°C for 4 hours. Chloroform was added to the reaction solution, washed with water, dried over anhydrous sodium sulfate and concentrated, and the main product was isolated from the resulting residue by preparative silica gel thin layer chromatography (solvent nitriethylamine-acetonitrile-chloroform). Add this to 0.15 d of 1N sodium hydroxide aqueous solution,
Heating was carried out for 45 minutes over an aqueous solution at 5-80°C. After cold contact, the reaction solution was filtered, the filtrate was neutralized with acetic acid, and then concentrated to about 0.1 -.The crystals that precipitated on standing were collected by filtration, washed successively with cold water and ether, and dried to obtain a solution with a melting point of 234~ 1.51Rg of the target product was obtained at 236.5°C (decomposition). Mass spectrometry (ra/e): 367 (M+2”),
365 (M+), 323 (100%), 279, 238 Example 21.8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-goberazinyl)- Synthesis of ethyl 3-quinolinecarboxylate 8-chloro-1-cyclopropyl-6,7-difluoro-1,4- was dissolved in 0.39 g of anhydrous piperazine in DMSO.
0.309 g of ethyl dihydro-4-oxo-3-quinolinecarboxylate was added and stirred at 50 to 60°C for 75 minutes. After cold welding, 10 d of chloroform and an aqueous potassium carbonate solution were added to the reaction mixture and shaken, the chloroform layer was separated, and the aqueous layer was further extracted three times with 5-chloroborum. Combine the chloroborum layers and add 3% dilute hydrochloric acid 5IIl! Then, chloroform 15- was added to the diluted hydrochloric acid layer, and the layers were quickly separated into IIHIO-11 with an aqueous sodium hydroxide solution.The chloroform layer was washed with water and dried with anhydrous sodium sulfate.
Acetone 10I11 was added to the residue and the precipitate was collected by filtration to obtain 0.089 of the desired product in the form of colorless needle-like crystals. Melting point 184-18
6°C Example 22.8-Chlor-1-cycloprogolu 6
-Fluoro-1,4-dihydro-4-oxo-7-(1
Synthesis of -piperazinyl)-3-quinolinecarboxylic acid and its hydrochloride 8-chloro-1-cyclopropyl-6-fluoro-1,
4-dihydro-4-oxo-7-(1-piperazinyl)
70 μ of ethyl -3-quinolinecarboxylate was added to 1.5 d of 1N aqueous sodium hydroxide solution, and the mixture was stirred for 30 minutes on an oil bath at 80 to 85°C. Activated carbon was added to the hot reaction solution and filtered, the filtrate was neutralized with acetic acid and left overnight at 5°C, the precipitated crystals were collected by filtration and the desired product 42a was obtained as a colorless prism product! I got J. Melting point: 244.5-246.5°C (decomposition) In addition, the above mother liquor has ra1! Add 5 drops of acid, collect the precipitated crystals by filtration, wash with cold water and ether, and prepare the salt of colorless prism crystals. ! Salt 13IyI was obtained. Melting point 260℃ (decomposition) Elemental analysis: Car Her C1FNa Oa ・H
zO calculation value C: 53,20)-1: 4.99
N: 10.95 actual value C: 53,291-1
: 4,70 N : 10.88 Elemental analysis: Car
Her Cj! FN303 ・1-1c, e Calculated value C: 50.76 H: 4.51 N: 10,
45 Actual value C: 50.66 H: 4.55 N
: 10.37 Example 23.8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-<4-
Synthesis of ethyl methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylate 8-chloro-1-cyclopropyl-6,7-difluoro0
-1.4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl 0.30 (J and N-methylbiperazine 0.30)
199 was reacted and post-treated in the same manner as in Example 21, and recrystallized from ethyl acetate to obtain the desired product 0.129 in the form of pale brown needle crystals. Melting point: 197-198°C Example 24.8-O-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and synthesis of its hydrochloride 8-chloro-1-cyclopropyl-6-fluoro-1,
4-dihydro-7-(4-methyl-1-piperazinyl)
-4-oxo-3-quinolinecarboxylic acid ethyl 110m
g was reacted and post-treated in the same manner as in Example 22 to obtain the desired product 2■ in the form of light brown needle-like crystals. Melting point: 300°C or higher, mass spectrometry (m
/e): 381 (M+2>, 379 (M+, 1
00%), 335.299° 79° of its hydrochloride salt in the form of colorless needles was also obtained. Melting point 218℃ (decomposition) Elemental analysis + (, I8HogC, eFN303・HCj
!・415Hz O Calculated value C: 50.20 H: 5.05 N:
9.76 Actual value C: 50.13 H: 4.75
N: 9.796, Table 1 on pages 26-27 of Book I is corrected as follows.

Claims (1)

【特許請求の範囲】 1、一般式 (式中、Rは水素、メチルまたはp−アミノペンデルを
、Yは塩素、弗素またはメチルを示す)で表わされる化
合物およびその水和物並びにその塩。
[Claims] 1. Compounds represented by the general formula (wherein R represents hydrogen, methyl or p-aminopendel, and Y represents chlorine, fluorine or methyl), hydrates thereof, and salts thereof.
JP23256083A 1983-12-09 1983-12-09 Quinolonecarboxylic acid derivative Pending JPS60126271A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP23256083A JPS60126271A (en) 1983-12-09 1983-12-09 Quinolonecarboxylic acid derivative
IN353/MAS/84A IN159604B (en) 1983-12-09 1984-05-14
PT7961684A PT79616A (en) 1983-12-09 1984-12-05 Process for the preparation of quinolonecarboxylic acid derivatives
DK586284A DK586284D0 (en) 1983-12-09 1984-12-07 QUINOLONCARBOXYLIC ACID DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND USING SUCH DERIVATIVES AS MEDICINAL
FI844839A FI844839L (en) 1983-12-09 1984-12-07 FOERFARANDE FOER FRAMSTAELLNING AV ANTIBAKTERIELLT AKTIVIN KINOLONKARBOXYLSYRADERIVAT.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23256083A JPS60126271A (en) 1983-12-09 1983-12-09 Quinolonecarboxylic acid derivative

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP19019984A Division JPS60222462A (en) 1984-09-11 1984-09-11 Quinolone carboxylic acid and its production
JP19020084A Division JPS60222448A (en) 1984-09-11 1984-09-11 Aniline compound and its production

Publications (1)

Publication Number Publication Date
JPS60126271A true JPS60126271A (en) 1985-07-05

Family

ID=16941239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23256083A Pending JPS60126271A (en) 1983-12-09 1983-12-09 Quinolonecarboxylic acid derivative

Country Status (5)

Country Link
JP (1) JPS60126271A (en)
DK (1) DK586284D0 (en)
FI (1) FI844839L (en)
IN (1) IN159604B (en)
PT (1) PT79616A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215572A (en) * 1986-03-17 1987-09-22 Kyorin Pharmaceut Co Ltd Quinolone carboxylic acid derivative
GB2188317A (en) * 1986-02-25 1987-09-30 Otsuka Pharma Co Ltd 4-oxo-quinoline compounds
JPS63264461A (en) * 1986-02-25 1988-11-01 Otsuka Pharmaceut Co Ltd Benzohetero ring compound and antibacterial agent containing said compound
JPH01125371A (en) * 1987-08-21 1989-05-17 Warner Lambert Co Quinolone and naphthildine antibacterial agent
US5103040A (en) * 1988-06-21 1992-04-07 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
US5233091A (en) * 1988-06-21 1993-08-03 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
JPH0680640A (en) * 1986-01-21 1994-03-22 Kyorin Pharmaceut Co Ltd 8-alkoxyquinolonecarboxylic acid having excellent selective toxicity, its salt and its production

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680640A (en) * 1986-01-21 1994-03-22 Kyorin Pharmaceut Co Ltd 8-alkoxyquinolonecarboxylic acid having excellent selective toxicity, its salt and its production
JPH0692937A (en) * 1986-01-21 1994-04-05 Kyorin Pharmaceut Co Ltd 8-alkoxyquinolonecarboxylic acid excellent in selective toxicity and salt thereof and its production
US4880806A (en) * 1986-02-25 1989-11-14 Otsuka Pharmaceutical Company, Limited 1-Cyclopropyl-6-fluoro-7-piperazinyl-1,4-Dihydro-4-oxo-quinoline-3-carboxylic acid derivatives
JPS63264461A (en) * 1986-02-25 1988-11-01 Otsuka Pharmaceut Co Ltd Benzohetero ring compound and antibacterial agent containing said compound
US4874764A (en) * 1986-02-25 1989-10-17 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
GB2188317B (en) * 1986-02-25 1990-04-18 Otsuka Pharma Co Ltd 4-oxo-quinoline compounds
DE3705621A1 (en) * 1986-02-25 1987-10-15 Otsuka Pharma Co Ltd HETEROCYCLICALLY SUBSTITUTED CHINOLONIC CARBONIC ACID DERIVATIVES
GB2188317A (en) * 1986-02-25 1987-09-30 Otsuka Pharma Co Ltd 4-oxo-quinoline compounds
JPS62215572A (en) * 1986-03-17 1987-09-22 Kyorin Pharmaceut Co Ltd Quinolone carboxylic acid derivative
US4894458A (en) * 1986-03-17 1990-01-16 Kyorin Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivatives and their preparation
JPH01125371A (en) * 1987-08-21 1989-05-17 Warner Lambert Co Quinolone and naphthildine antibacterial agent
US5103040A (en) * 1988-06-21 1992-04-07 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
US5233091A (en) * 1988-06-21 1993-08-03 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor

Also Published As

Publication number Publication date
FI844839L (en) 1985-06-10
PT79616A (en) 1985-01-01
DK586284D0 (en) 1984-12-07
FI844839A0 (en) 1984-12-07
IN159604B (en) 1987-05-30

Similar Documents

Publication Publication Date Title
EP0287951B1 (en) 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents
JP2604124B2 (en) Naphthyridine derivative
EP0172651B1 (en) Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds
KR940007305B1 (en) 8-substituted quinolone carboxylic acid derivative
TW202442B (en)
CA1262349A (en) Pyridonecarboxylic acid derivatives and process for their preparation
JP2504895B2 (en) 1-amino-2,2-difluorocyclopropane
DK173185B1 (en) 1-Cyclopropyl-7- [3- (substituted amino) methyl-1-pyrrolidinyl] -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid derivatives
JPS60126271A (en) Quinolonecarboxylic acid derivative
DD265401A5 (en) PROCESS FOR THE PREPARATION OF 7- (AZABICYCLOACYL) -QUINOLINE CARBOXYLIC ACID AND NAPHTHYDRIDE CARBOXYLIC ACID DERIVATIVES
DK161383B (en) QUINOLINCARBOXYLIC ACID DERIVATIVE, PROCEDURE FOR PREPARING IT, AND ANTIBACTERIAL PHARMACEUTICAL PREPARATIONS CONTAINING THIS
US4703047A (en) 1-Cyclopropyl-1,4-dihydro-4-oxo-7-(4-(2-oxo-1,3-dioxol-4-yl-methyl)-1-piperazinyl)-3-quinolinecarboxylic acid antibacterial agents
US5290934A (en) Benzoheterocyclic compounds
CN111848508A (en) Method for preparing quinoline compound
JP2001502682A (en) Method for preparing N- [2- (dimethylamino) ethyl] acridine-4-carboxamide
JPS63264461A (en) Benzohetero ring compound and antibacterial agent containing said compound
JPH0348682A (en) Pyridonecarboxylic acid compound
JPS6259263A (en) Quinolonecarboxylic acid derivative
JP2523092B2 (en) Benzene derivative
KR890005200B1 (en) 7-(1-pyrrolidinyl) quinoline carboxylic-acid derivatives
JPH03115264A (en) Antibacterial agent
AU610491B2 (en) 8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same
JPH03135930A (en) Benzene derivative
JPS62226962A (en) Novel quinolone derivative, ester and salt thereof
JPH0680640A (en) 8-alkoxyquinolonecarboxylic acid having excellent selective toxicity, its salt and its production